Archive for June, 2014

(FUEL) Launches Audience Guarantee

Denny’s Uses Rocket Fuel Audience Guarantee to Maximize In-Target Reach and Brand Effectiveness Across Programmatic Video Buys

REDWOOD CITY, CA–(Jun 23, 2014) – Rocket Fuel (NASDAQ: FUEL), a leading provider of artificial intelligence (AI) advertising solutions for digital marketers, today launched Rocket Fuel Audience Guarantee, the first programmatic buying solution to provide optimal reach for advertisers across video and display channels against leading third-party measurement vendors, Nielsen Online Campaign Ratings (OCR) and comScore validated Campaign Essentials (vCE). Rocket Fuel Audience Guarantee expands upon Rocket Fuel’s suite of capabilities for brand marketers, helping digital marketers reach specific audiences and maximize brand impact across all digital touch points.

As viewing behavior continues to fragment across TV and digital, reaching the right audience at the moment of influence is more critical than ever before. For brand marketers, Rocket Fuel’s artificial intelligence engine now runs with continuous optimization inputs from Nielsen’s OCR and comScore’s vCE, and selects impressions to ensure marketers reach a high composition of their desired audiences..

Rocket Fuel has already seen promising results helping leading brands such as Denny’s (http://rocketfuel.com/resources/case-study/performs-60-better) to maximize branding impact within their target audience at scale. In a recent campaign, Denny’s was looking to drive Brand Consideration within Males 25-54, where the current industry on-target average is just 41% according to comScore. (comScore vCE Q2 2014 Benchmarks)

“Scaling the Denny’s programs to key customer segments across channels has been a big focus. We’re very impressed by Rocket Fuel’s results,” said Breta Rae Kennedy, associate media director for the Denny’s team at Optimedia San Francisco. “Rocket Fuel delivered on-target reach with consistent performance 60% better than market norms and was also able to deliver 33% lift in brand consideration.”

Audience Guarantee is a core component of the Rocket Fuel Brand Advertising Suite, which

  • enables programmatic access to high quality and viewable inventory across video, display and mobile exchanges
  • offers in-target audience delivery at incredible scale
  • increases brand lift through real-time optimization to consumer surveys, maximizing impact on key branding objectives such as Awareness, Favorability and Purchase Intent
  • improves offline sales outcomes and media ROI by optimizing to in-store sales as measured by Nielsen Catalina Solutions

“Rocket Fuel’s Brand Advertising Suite serves brand marketers’ need to intensify branding impact on desired audiences. Until now, brand marketers have often had to resort to a ‘spray-and-pray’ method of video advertising that wastes more than half the budget,” said Simon Hayhurst, Senior Vice President of Product and Business Development at Rocket Fuel. “To drive meaningful impact for branding objectives, marketers need ads in the right place, at the right time, before their desired audience. With the addition of Audience Guarantee, total communications planning becomes easier for our customers since our platform not only outperforms on audience accuracy, but also optimizes brand lift for specific audiences.”

For more information, please visit http://www.rocketfuel.com/solutions/video.

About Rocket Fuel
Rocket Fuel delivers a leading programmatic media-buying platform at Big Data scale that harnesses the power of artificial intelligence (AI) to improve marketing ROI in digital media across web, mobile, video, and social channels. Rocket Fuel powers digital advertising and marketing programs globally for customers in North America, Europe, and Japan. Customers trust Rocket Fuel’s Advertising That Learns® platform to achieve brand and direct-response objectives in diverse industries from luxury cars to financial services to retail. Rocket Fuel currently operates in more than 20 offices worldwide and trades on the NASDAQ Global Select Market under the ticker symbol “FUEL.” For more information, please visit http://www.rocketfuel.com or call 1-888-717-8873.

Monday, June 23rd, 2014 Uncategorized Comments Off on (FUEL) Launches Audience Guarantee

(NEO) Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Q2

Company Experiencing Strong Test Volume Growth

FT. MYERS, Fla., June 23, 2014  — NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue guidance for Quarter 2, 2014.  The Company now expects revenue of approximately $20.0 – $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 – $19.3 million.  The Company also reaffirmed its previously issued earnings per share guidance of $0.00 – $0.01 for the quarter.

Doug VanOort, the Company’s Chairman and CEO, commented, “We experienced exceptionally strong year-over-year volume growth in April and May driven by a continued increase in the number of new customer accounts.  We are pleased by these market share gains and by the outstanding level of customer retention our teams are achieving.  The growth is geographically broad-based, and is being fueled by the increased size and productivity of our sales team and by new product activity.  At the mid-point of the revised guidance range, revenue growth would approximate 30% compared with last year’s second quarter.  We look forward to sharing our full second quarter financial results, reviewing additional growth initiatives, and updating our full year 2014 revenue and earnings guidance as part of our Q2 Earnings Release on July 17, 2014.”

The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan.  Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.

Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from Zack’s Investment Research at http://www.zacks.com or scr@zacks.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.

Monday, June 23rd, 2014 Uncategorized Comments Off on (NEO) Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Q2

(TGD) Announces Four New Independent Nominees For Board

VANCOUVER, BRITISH COLUMBIA–(June 23, 2014) – Timmins Gold Corp. (TSX:TMM)(NYSE MKT:TGD) (“Timmins Gold” or the “Company”) announced today the nomination of four new, highly-qualified mining industry professionals to stand for election as part of an independent seven-person Board of Directors.

“The four new nominees will work alongside three incumbent directors to build value for all shareholders,” said Paula Rogers, chair of the Special Committee of independent directors. “This enhanced, independent Board will collectively have more than 170 years of relevant experience. If elected, we will continue to execute on and evaluate Timmins Gold’s proven business strategy, which has delivered superior performance and shareholder return.”

Board Renewal Process

The Special Committee was formed to oversee the Company’s response to a dissident campaign by Sentry Investments Inc. Through a rigorous Board renewal process the Special Committee identified and recruited the four new independent nominees.

As part of the Board renewal process, the Special Committee:

  • took into account Sentry’s expressed concerns;
  • engaged an independent legal advisor and Korn Ferry International, the leading international executive search firm;
  • received input from some of the Company’s largest shareholders; and
  • received input from RBC Capital Markets, which Timmins Gold has engaged as its financial advisor.

“The Board and the new nominees believe that the Board renewal process achieves many of the objectives sought by the dissident that are also of benefit to all shareholders” said Ms. Rogers. “Moreover, the Board renewal will preserve the knowledge and experience of Timmins Gold’s operational and corporate management if the Timmins Gold Nominees are elected. This knowledge and experience will be lost if a dissident board is elected.”

New Independent Director Nominees

All four new nominees are proven leaders with successful track records. They will bring unequalled technical, operational, financial and market expertise to our Board. Set out below is a brief biography of each of the new nominees:

  • George Brack, 52, has spent 29 years in the mining industry and in mining-focused investment banking. From 2000 to 2009 he was a mining-focused investment banker, serving successively as President and CEO of Macquarie North America and Managing Director, Industry Head, Mining with Scotia Capital Inc. Among other things, as an investment banker he advised clients on the sale of public companies and projects involving five gold mining assets in Mexico. From 1995 to 1999 he was Vice-President, Corporate Development for one of Canada’s largest gold miners, Placer Dome Inc. He is currently a director of several companies including Silver Wheaton Corp. and Capstone Mining Corp. He served as chair of the special committee of the boards of both Red Back Mining Inc. in 2010 and Aurizon Mines Ltd. in 2013 when they were acquired for $7.2 billion and $796 million, respectively. He has an MBA degree from York University, a Bachelor of Applied Science degree in Geological Engineering from the University of Toronto and has earned the Chartered Financial Analyst designation.
  • Bryan Coates, 56, has spent 30 years in the mining industry. He currently serves as President of Osisko Gold Royalties Ltd. and previously was VP Finance and Chief Financial Officer for Osisko Mining Corp. from 2007 until it was acquired earlier this month for $3.9 billion. Osisko developed and operated the Canadian Malartic mine, the largest gold mine in Quebec, and also conducted exploration work in Mexico. Before Osisko he served as VP Finance and Chief Financial Officer for IAMGOLD Corp. and Cambior Inc. Mr. Coates is a director of Golden Queen Mining Co. He has a Bachelor of Commerce degree from Laurentian University, and has earned the Chartered Accountant designation.
  • Stephen Lang, 58, a mining engineer, has spent more than 32 years in the mining industry. He is currently chair of Centerra Gold Inc., one of the largest gold miners in Asia. From 2008 to 2012, prior to becoming chair, he was Centerra’s President and CEO. His prior experience includes serving as Executive VP and Chief Operating Officer of Stillwater Mining Co., and managing large mines for Barrick Gold Corp and Kinross Gold Corp. He has recently become a director of both Allied Nevada Gold Corp. and International Tower Hill Mines Ltd. For International Tower Hill he also serves as chair. He has a Master of Science degree and a Bachelor of Science degree from the University of Missouri-Rolla.
  • Luc Lessard, 50, a mining engineer, has spent more than 25 years designing, constructing and operating mining projects. He currently serves as Senior VP and Chief Operating Officer of Canadian Malartic Partnership and previously was Senior Vice President and Chief Operating Officer of Osisko Mining Corp. from 2011 until it was acquired earlier this month for $3.9 billion. He was Osisko’s VP, Engineering and Construction from 2007 to 2011, during which time he was directly responsible for the design and construction of the Canadian Malartic gold mine. He previously served as VP Engineering and Construction for IAMGOLD Corp. and as General Manager, Projects for Cambior Inc. during which time he was responsible for the construction of the Rosebel gold mine in Suriname. He has a Bachelor of Applied Science degree from Université du Laval, a College Degree in Mining Technologies from Collège de la Région de l’Amiante, and he has earned the Professional Engineer designation from the Canadian Council of Professional Engineers. Mr. Lessard is a director of Nighthawk Gold Corp.

Incumbent Director Nominees and Retiring Directors

Only one of the three incumbent directors nominated for election is a member of the management team – Chief Executive Officer Bruce Bragagnolo. The other two incumbent directors nominated for election are independent. As a result, if all seven Timmins Gold Nominees are elected, 86% of the Timmins Gold Board (6 of 7) will be independent.

As CEO, Mr. Bragagnolo oversees the strategic vision, administration and finance of the Company. He is 57 and has more than 27 years of experience in the natural resource sector both as a lawyer and a director. He has been responsible for structuring and raising over $100 million in equity and debt for Timmins Gold and overseeing the growth of the Company as it transitioned from junior developer to gold producer. As CEO he has guided the Company to industry-leading financial metrics.

Mr. Bragagnolo is a co-founder of Timmins Gold, along with Arturo Bonillas, President of Timmins Gold. Their leadership is largely responsible for the success of Timmins Gold and its outperformance when compared with peers. Messrs. Bragagnolo and Bonillas are among Timmins Gold’s top ten shareholders, with a significant combined ownership of 3.3% of the issued and outstanding shares. Their interests, and the interests of the management team as a whole, are strongly aligned with the interests of shareholders and their decisions are made with a view to building long term shareholder value.

Below are brief biographies of the two independent incumbent directors:

  • Paula Rogers, 45, joined the Board in 2011. She is a Chartered Professional Accountant and brings over 20 years of experience working for Canadian-based international public companies in the areas of treasury, mergers and acquisitions, financial reporting and tax. She has extensive experience in the mining industry in both director and officer roles. Ms. Rogers is currently the CFO of Castle Peak Mining Ltd. and director and chair of the Audit Committee of Athabasca Uranium Inc. She has served as Vice-President, Treasurer of Goldcorp Inc., Treasurer of Wheaton River Minerals Ltd. and Treasurer of Silver Wheaton Corp. She has worked on several significant transactions including the spin-out of Silver Wheaton from Wheaton River Minerals and Goldcorp’s acquisition of the Canadian assets of Placer Dome from Barrick Gold. She holds a Bachelor of Commerce degree from the University of British Columbia.
  • Jose Vizquerra Benavides, 34, joined the Board in 2013. Mr. Vizquerra is currently President, CEO and a director of Oban Mining Co. and has more than ten years of experience in mining. From 2008 until 2011 Mr. Vizquerra was the head of project evaluations with Compania de Minas Buenaventura of Lima, Peru, and from 2005 until 2008 he was a geologist with Goldcorp. Mr. Vizquerra is fluent in both Spanish and English. Mr. Vizquerra holds a Master of Science degree in Mineral Exploration from Queen’s University and a Bachelor of Civil Engineering degree from the Peruvian University of Applied Science. He has earned the Certified Professional Geologist designation from the American Institute of Professional Geologists.

Mr. Bonillas and four other long-serving directors, Frank Cordova, Barry Fraser, Eugene Hodgson and Miguel Soto, will not be standing for re-election. The Company thanks each of them for their many years of dedicated service as directors and for their many contributions to the development of the Company, and its evolution into the sustainable producing mine operator it is today.

Mr. Bonillas will continue to serve as President of the Company with overall responsibility for the Company’s operations. Mr. Soto will continue to serve as VP Exploration. Mr. Cordova has agreed to serve as a special advisor to the Board with respect to local matters.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) nor the NYSE MKT accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained herein may constitute forward-looking statements and are made pursuant to the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Forward-looking statements are statements which relate to future events. Such statements include estimates, forecasts and statements as to management’s expectations with respect to, among other things, business and financial prospects, financial multiples and accretion estimates, future trends, plans, strategies, objectives and expectations, including with respect to production, exploration drilling, reserves and resources, exploitation activities and events, future operations, organic growth, mergers and acquisitions and the appointment of new directors.

In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans, “anticipates”, believes”, “estimates”, “predicts”, “potential”, or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggestions herein. Except as required by applicable law, Timmins Gold does not intend to update any forward-looking statements to conform these statements to actual results.

Timmins Gold Corp.
Alex Tsakumis
Vice President, Corporate Development
604-682-4002
alex@timminsgold.com
www.timminsgold.com

For Media:
Longview Communications Inc.
Alan Bayless
604-694-6035
abayless@longviewcomms.ca

Monday, June 23rd, 2014 Uncategorized Comments Off on (TGD) Announces Four New Independent Nominees For Board

(NSPH) Signs Molecular Diagnostic Supply Agreement With HealthTrust

NORTHBROOK, Ill., June 23, 2014  — Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership.

Under this agreement, HealthTrust will offer its members access to purchase Nanosphere’s portfolio of Verigene® multiplex molecular diagnostic infectious disease tests, including those designed to rapidly and accurately detect infections of the bloodstream, respiratory tract and gastrointestinal tract.

The agreement became effective on June 1, 2014.

Please contact your local sales representative or info@nanosphere.us for additional information.

About the Verigene® System

The Verigene System uses Nanosphere’s core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at nanosphere.us.

About HealthTrust

HealthTrust (legally known as HealthTrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust (www.healthtrustpg.com) serves nearly 1,400 acute care facilities, 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tennessee, HealthTrust is closely integrated with the proven capabilities of Parallon Business Solutions, LLC (www.parallon.com), a leading provider of healthcare business and operational services, including revenue cycle management, workforce and technology solutions.

CONTACT: Investors:
         Roger Moody, Chief Financial Officer
         847-400-9021
         rmoody@nanosphere.us

         Michael Rice, LifeSci Advisors
         646-597-6979
         mrice@lifesciadvisors.com

         Media:
         Lindsey Saxon, Director of Communications
         847-400-9173
         lsaxon@nanosphere.us
Monday, June 23rd, 2014 Uncategorized Comments Off on (NSPH) Signs Molecular Diagnostic Supply Agreement With HealthTrust

(OHRP) Conference Call and Webcast Squalamine Interim Phase II Data in Wet-AMD

Webcast to be Held on Tuesday, June 24 at 8:30am Eastern
Webcast & Slides Available at www.OhrPharmaceutical.com

NEW YORK, June 23, 2014  — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will host a conference call and webcast on Tuesday, June 24th to discuss Squalamine interim Phase II data in wet age-related macular degeneration (“wet-AMD”).

Tuesday, June 24, 2014 @ 8:30am Eastern Time
Toll Free: 877-407-0789
International: 201-689-8562
Webcast: www.ohrpharmaceutical.com
Replays through July 8, 2014:
Toll Free: 877-870-5176
International: 858-384-5517
Replay PIN: 13585479

About Squalamine Eye Drops

Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors implicated in the angiogenesis process. Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine for the treatment of wet-AMD, designed for self-administration, which may provide several potential advantages over the FDA approved current standards of care, which require intravitreal injections directly into the eye. The drug, using an intravenous administration in over 250 patients in Phase I and Phase II trials for the treatment of wet-AMD, showed favorable biological effect and maintained and improved visual acuity outcomes. In May 2012, the Squalamine Eye Drop program was granted Fast Track Designation by the U.S. FDA.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Inc. (OHRP) is a research and development company with a primary focus in ophthalmology. The Company’s lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase 2 clinical trials for various back-of-the-eye diseases, including the wet form of age related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. Ohr is also developing OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

CONTACT: Company Contact:
         Ohr Pharmaceutical Inc.
         Investor Relations
         (877) 215-4813
         ir@ohrpharmaceutical.com

         Media Contact:
         Laura Bagby
         6 Degrees Communications
         872-206-5475
         lbagby@6degreespr.com

         Investor Contact:
         LifeSci Advisors, LLC
         Andrew McDonald
         646-597-6987
         andrew@lifesciadvisors.com
Monday, June 23rd, 2014 Uncategorized Comments Off on (OHRP) Conference Call and Webcast Squalamine Interim Phase II Data in Wet-AMD

(VNRX) Sells First NuQ® Research Use Only Kits to Active Motif

First revenues from VolitionRx Nucleosomics technology

NAMUR, Belgium, June 23, 2014  — VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces its first wholesale order of NuQ® Research Use Only kits to Active Motif. Each kit allows epigenetics researchers to identify and analyze a different nucleosome structure. Active Motif will distribute the kits in its key markets of Europe, the United States and Japan.

These assays allow researchers — in areas as diverse as stem cells, apoptosis and epigenetic regulation — to study nucleosome based epigenetic features in animal or human cell culture samples. The four different types of kits which will be available through Active Motif are:

  • NuQ® Total Nucleosome Cell Culture ELISA (measures total nucleosomes in a cell culture sample)
  • NuQ® H4K16(Ac) Cell Culture ELISA (measures nucleosome associated acetylated lysine 16 on histone H4 in a cell culture sample)
  • NuQ® H4Pan(Ac) Cell Culture ELISA (measures nucleosome associated total acetylation on nucleosome associated H4 in a cell culture sample)
  • NuQ® H2AZ Cell Culture ELISA (measures nucleosome associated histone variant H2AZ in a cell culture sample)

Cameron Reynolds, CEO of VolitionRx, commented, “Active Motif is a globally respected supplier of tools for use in the field of epigenetics research, so we are delighted to be partnering with them. Our kits have great potential in supporting cell culture research and we are excited to see them being made available through Active Motif’s sales and distribution network and to their extensive customer base. It’s fantastic for us to see our first revenues from Nucleosomics.”

“VolitionRx’s NuQ® ELISA research kits are an excellent complement to our existing range of epigenetics research products,” Gary Shiels PhD, Director of Global Marketing at Active Motif added. “We are always looking for innovative tests that can enable our researchers to track unique epigenetic characteristics and inspire them to experiment with new techniques.”

These kits are for research use only and are not approved for in vitro medical use. VolitionRx’s NuQ® epigenetics Research Use kits are also available via www.nucleosomics.com for a sales price of EUR495-EUR795, depending on the kit target.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx’s website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

About Active Motif

Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions; biotechnology and pharmaceutical companies; hospitals and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California regional headquarters in Belgium and Japan and a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

Media Contacts:

Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: charlotte.reynolds@volitionrx.com

Eleanor Stuart, Racepoint Global
Telephone: +44 (0) 208 811 2124
Email: eleanor.stuart@racepointglobal.com

Investor Contact:

Scott Powell, VolitionRx
Telephone: +1 917 721 9480
Email: s.powell@volitionrx.com

Active Motif Contact:

Gary Shiels, Active Motif
Telephone: 760 431 1263
Email: shiels@activemotif.com

Safe Harbor Statement

Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Monday, June 23rd, 2014 Uncategorized Comments Off on (VNRX) Sells First NuQ® Research Use Only Kits to Active Motif

(GST) to Present at the Global Hunter Securities 100 Energy Conference in June

HOUSTON, June 20, 2014  — Gastar Exploration Inc. (NYSE MKT: GST) announced that the Company’s management will participate in the GHS 100 Energy Conference to be held June 24-25 in Chicago.

J. Russell Porter, President and Chief Executive Officer, will make a presentation at 2 p.m. Central Time on Tuesday, June 24.  The presentation will provide an update on the Company’s operations and certain recent developments.

To listen to a live audio webcast and view the presentation materials, visit the Investor Relations section of the Company’s website at www.gastar.com under Events and Presentations.  A replay will also be available for rebroadcast on the Company’s website.

About Gastar Exploration

Gastar Exploration Inc. is an independent energy company engaged in the exploration, development and production of oil, natural gas, condensate and natural gas liquids in the United States.  Gastar’s principal business activities include the identification, acquisition, and subsequent exploration and development of oil and natural gas properties with an emphasis on unconventional reserves, such as shale resource plays. Gastar is currently pursuing development within the primarily oil-bearing reservoirs of the Hunton Limestone horizontal oil play in Oklahoma and the development of liquids-rich natural gas in the Marcellus Shale play and dry gas in the Utica Shale play in West Virginia.  For more information, visit Gastar’s website at www.gastar.com.

Contacts:
Gastar Exploration Inc.
J. Russell Porter, Chief Executive Officer
713-739-1800 / rporter@gastar.com

Investor Relations Counsel:
Lisa Elliott / lelliott@DennardLascar.com
Anne Pearson / apearson@DennardLascar.com
Dennard ▪ Lascar Associates: 713-529-6600

Friday, June 20th, 2014 Uncategorized Comments Off on (GST) to Present at the Global Hunter Securities 100 Energy Conference in June

(LLEX) Regains NASDAQ Compliance

DENVER, June 20, 2014  — Lilis Energy, Inc. (Nasdaq:LLEX), announced today that it has been informed by The NASDAQ Stock Market that, based on the June 11 and 17, 2014 filings of the Company’s Form 10-K for the fiscal year ended December 31, 2013 and Form 10-Q for the period ended March 31, 2014, respectively, that the Company complies with the periodic filing requirement of Rule 5250(c)(1).

About Lilis Energy, Inc.

Lilis Energy, Inc. is a Denver-based independent oil and gas exploration and production company that operates in the Denver-Julesburg (DJ) Basin where it holds approximately 123,000 gross, 107,000 net acres. Lilis Energy’s near-term E&P focus is to grow reserves and production in its Greater Wattenberg field leasehold targeting the Niobrara benches and Codell Sandstone. For more information, please contact MDC Group: Investors – (414) 351-9758, Media – (747) 222-7012, or visit www.lilisenergy.com.

Forward Looking Statements

This press release may include or incorporate by reference “forward-looking statements” as defined by the SEC, including statements, without limitation, regarding Lilis Energy’s expectations, beliefs, intentions or strategies regarding the future. Such forward-looking statements relate to, among other things Lilis Energy’s near-term E&P focus on its Wattenberg Field acreage. These statements are qualified by important factors that could cause Lilis Energy’s actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to Lilis Energy’s ability to finance its continued exploration and drilling operations and the general risks associated with oil and gas exploration and development, including those risks and factors described from time to time in Lilis Energy’s reports and registration statements filed with the SEC.

Contact:
MDC GROUP
Investor Relations: Media Relations:
David Castaneda Susan Roush
414.351.9758 747.222.7012
Friday, June 20th, 2014 Uncategorized Comments Off on (LLEX) Regains NASDAQ Compliance

(NYNY) on Preliminary Russell 2000 and Russell 3000 Index Lists

Empire Resorts, Inc. (together with its subsidiaries, “Empire”) (NASDAQ-GM:NYNY) has been added to the preliminary lists of companies scheduled to become part of the Russell 2000 and Russell 3000 Indexes when Russell Investments (“Russell”) reconstitutes its U.S. and global equity indexes on June 27, 2014.

Empire’s addition to the Russell 2000 and Russell 3000 Indexes is part of Russell Investments’ annual index reconstitution process that is done to maintain a true representation of global equity markets, capitalization and style. Russell posted the annual list of preliminary index additions, which includes Empire, on www.russell.com, on June 13, 2014. Russell will provide updates to the list of additions and deletions on June 20 and 27. The lists will be finalized when Russell formally reconstitutes its equity indexes after market close on June 27, 2014 and the final membership lists will be posted for the indexes on June 30.

About Empire Resorts

Empire Resorts owns and operates, through its subsidiary Monticello Raceway Management, Inc., the Monticello Casino & Raceway, a harness racing track and casino located in Monticello, New York, and is 90 miles from midtown Manhattan. Further information is available at www.empireresorts.com.

Cautionary Statement Regarding Forward Looking Information

This press release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These statements include statements about our plans, strategies, financial performance, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Friday, June 20th, 2014 Uncategorized Comments Off on (NYNY) on Preliminary Russell 2000 and Russell 3000 Index Lists

(SHPG) Confirms Rejection of AbbVie Proposal

DUBLIN, June 20, 2014 —

Shire plc (“Shire” or the “Company”) (LSE: SHP, NASDAQ: SHPG) notes the announcement made by AbbVie Inc. (“AbbVie”) and confirms that on 30 May 2014, Shire received an unsolicited and highly conditional proposal from AbbVie (the “Proposal”) regarding a possible cash and share offer for Shire.  This Proposal has been rejected.

The Proposal comprised £20.44 in cash and 0.7988 AbbVie shares per Shire share. The Proposal involved a new US listed holding company with a UK tax domicile.

Based on AbbVie’s 30 day volume weighted average share price of US$54.10, the Proposal represents a value of £46.11 per Shire share (comprising 44% cash and 56% AbbVie shares).  The Proposal represents:

  • A premium of 23% to Shire’s share price of £37.38 on 19 June 2014 (the business day prior to this announcement); and
  • A premium of 30% to Shire’s 30 day volume weighted average share price of £35.43.

The Proposal follows two earlier proposals, which were also rejected. At AbbVie’s request, Shire met with AbbVie to enable AbbVie to explain key aspects of the Proposal.  Following this meeting, the Board of Shire decided unanimously to reject the Proposal on the basis that it fundamentally undervalued the Company and its prospects.

The Board also had concerns regarding the execution risks associated with the proposed inversion structure, as AbbVie would redomicile in the UK for tax purposes.

In particular, the Board of Shire believes:

  • The Proposal fundamentally undervalued Shire and its prospects as a leader in Rare Diseases and Specialty Markets
  • New management has achieved a step-change in Shire’s performance, resulting in significantly accelerated growth and increased shareholder returns over the last 12 months
  • Shire will more than double its 2013 annual product sales to US$10 billion by 2020
  • The Proposal would deny Shire shareholders the full benefits of Shire’s growth strategy

Susan Kilsby, Chairman of Shire, said: “Shire has a long track record of delivering for shareholders and addressing unmet patient needs.  Our high-performing management team and focused strategy are producing even stronger results, reflected in our recent top-line growth and increased profitability.

With an expanded portfolio focused on high-growth opportunities, an efficient cost base and an enhanced innovative pipeline, we have put in place a platform for long-term value creation.  We believe that Shire has a strong independent future.

The Board believes the Proposal fundamentally undervalued Shire and its prospects and that as an independent company Shire’s focused growth strategy will continue to deliver significant shareholder value and patient benefits.”

Shareholders are strongly advised to take no action in relation to the Proposal.  There can be no certainty that any firm offer will be made, nor as to the terms on which any firm offer might be made.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

Shire’s Strong Independent Prospects

The Board of Shire believes strongly that the Company has created a platform to deliver sustainable sales growth and superior patient outcomes.  The Board’s confidence is built upon the Company’s strong track record of growth and transformation under new management.

From 2008 to 2013, Shire’s product sales increased at a compound annual rate of 11.6% and Non GAAP diluted earnings per ADS grew at a compound annual rate of 14.7% over the same time frame(1).

New management has since sharpened strategic focus and improved operational discipline, achieving a step-change in Shire’s performance.  These initiatives have produced:

  • 19% product sales growth from Q12013 to Q12014
  • Non GAAP EBITDA margin up eight percentage points over the last year from 37% (Q12013) to 45% (Q12014)(2)
  • Rare Diseases business unit growth to US$2 billion in product sales to become Shire’s largest business unit(3)
  • An innovative pipeline significantly strengthened with multiple late stage opportunities
  • Total shareholder returns, including reinvestment of dividends, of 99% from 2 May 2013 to 19 June 2014 (the business day prior to this announcement)

Shire has assembled the core elements required to drive innovation and generate superior returns over the long-term with an experienced and high-performing management team, enhanced capabilities and lean infrastructure, competitive operational and financial scale, and a portfolio focused on high-growth opportunities.  These elements are reflected in Shire’s Long Range Plan (“LRP”).

The LRP was updated as part of Shire’s normal annual planning cycle in September 2013 and was reviewed by the Board in October 2013.  A revised LRP was developed to reflect the acquisition of ViroPharma, the disposal of Dermagraft, the termination of the Vyvanse Major Depressive Disorder program, 2013 full year reported financial results and other events in 2014.  This revised LRP was reviewed by the Board most recently in June 2014.

The LRP underpins the Board’s confidence that Shire will deliver double-digit compound annual product sales growth from its current portfolio through 2020, more than doubling its 2013 annual product sales to US$10 billion. Furthermore, the LRP does not include the potential upside from further accretive M&A.

Investor Call

The Company will be hosting an investor call on Monday, 23 June 2014.  Details of this call will be provided in due course.

Key Sources, Bases and Assumptions

The Shire forecasts and targets included in this announcement are derived from Shire’s LRP, business papers produced to support the LRP and Shire papers subsequently produced as part of the business planning process.

The forecast product sales targets in this announcement are consistent with the LRP for the period from 2014 to 2020, which is at constant exchange rates, and reflects net sales for each product and key line extensions currently identified as in Phase III, Phase II and those in (or soon to enter) Phase I included in the LRP as launching before the end of 2020.

The forecast product sales included in the LRP are risk-adjusted to reflect Shire’s assessment of the individual probability of launch of products in development, and the probability of success in further life cycle management trials.  Estimates for these probabilities are based on industry wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development.

For each pharmaceutical product, there is a range of possible outcomes from clinical development, driven by a number of variables, including safety, efficacy and product labelling.  In addition, if a product is approved, the effect of commercial factors including the patient population, the competitive environment, pricing and reimbursement is also uncertain.  As a result, the actual net sales achieved by a product over its commercial life will be different, perhaps materially so, from the risk adjusted net sales figures in this announcement and should be considered in this light.

Attention is drawn to the notice set out under the heading Forward-Looking Statements below.

Notes

The first proposal from AbbVie, received on 5 May 2014, comprised £16.23 in cash and 0.7680 AbbVie shares per Shire share, representing a value of £38.97 per Shire share (based on AbbVie’s 30 day volume weighted average share price of US$49.64).  The second proposal from AbbVie received on 13 May 2014, comprised £17.13 in cash and 0.7680 AbbVie shares per Shire share, representing a value of £39.96 per Shire share (based on AbbVie’s 30 day volume weighted average share price of US$50.05). The Board of Shire unanimously rejected both proposals.

The value of the 5 May 2014 proposal of £38.97 is based on US$49.64 per AbbVie share (30 day volume weighted average share price to 2 May 2014 (the business day prior to the 5 May 2014 proposal being received)) and a GBP/US$ foreign exchange rate of 1/1.6761 (30 day average exchange rate to 2 May 2014).  US$49.64 per AbbVie share (30 day volume weighted average share price) is calculated using the price and volume of each AbbVie share trade between 3 April 2014 and 2 May 2014 as provided by Bloomberg.

The value of the 13 May 2014 proposal of £39.96 is based on US$50.05 per AbbVie share (30 day volume weighted average share price to 12 May 2014 (the business day prior to the 13 May 2014 proposal being received)) and a GBP/US$ foreign exchange rate of 1/1.6836 (30 day average exchange rate to 12 May 2014).  US$50.05 per AbbVie share (30 day volume weighted average share price) is calculated using the price and volume of each AbbVie share trade between 13 April 2014 and 12 May 2014 as provided by Bloomberg.

The 30 day volume weighted average share price value of the Proposal of £46.11 is based on US$54.10 per AbbVie share (30 day volume weighted average share price to 19 June 2014 (the business day prior to this announcement)) and a GBP/US$ foreign exchange rate of 1/1.6836 (30 day average exchange rate to 19 June 2014).  US$54.10 per AbbVie share (30 day volume weighted average share price) is calculated using the price and volume of each AbbVie share trade between 21 May 2014 and 19 June 2014 as provided by Bloomberg.

£37.38 per Shire share on 19 June 2014 (the business day prior to this announcement) is provided by the London Stock Exchange.

£35.43 per Shire share (30 day volume weighted average share price) is calculated using the price and volume of each Shire share trade between 21 May 2014 and 19 June 2014 as provided by the London Stock Exchange.

  1. On a US GAAP basis diluted earnings per ADS compound annual growth rate was 32.7% over the same 2008 to 2013 period.
  2. The most directly comparable measure under US GAAP is net income, which was US$230 million in Q12014 (Q12013: $65 million).
  3. Product sales of US$2 billion for the 2013 financial year on a pro forma basis including Cinryze product sales (which was acquired in January 2014).

 

A copy of this announcement will be available at http://www.Shire.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

We provide treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

Shire’s product sales from continuing operations have increased from US$2,754 million in the financial year to 31 December 2008 to US$4,757 million in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 11.6%. Shire’s Non GAAP diluted earnings per ADS have increased from US$3.86 in the financial year to 31 December 2008 to US$7.66 in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 14.7%.   Shire’s US GAAP diluted earnings per ADS have increased from US$0.86 in the financial year to 31 December 2008 to US$3.53 in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 32.7%.

http://www.shire.com

RULE 2.10 REQUIREMENT

In accordance with Rule 2.10 of the Code, the Company confirms that as at close of business on 19 June 2014, its issued share capital consisted of 589,204,321 ordinary shares of 5 pence each, with ISIN Number JE00B2QKY057, which carry voting rights of one vote per share.

Shire has an American Depositary Share (“ADS”) programme for which Citibank, N.A. acts as Depositary.  One ADS represents three ordinary shares of 5 pence each, with ISIN Number US82481R1068.  The ADSs trade on the NASDAQ Global Select Market.

DISCLOSURE REQUIREMENTS OF THE TAKEOVER CODE (THE “CODE”)

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s).  An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified.  Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror.  A Dealing Disclosure must contain details of the dealing concerned and of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8.  A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel’s website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified.  If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel’s Market Surveillance Unit on +44(0)20-7638-0129.

FURTHER INFORMATION

Evercore Partners International LLP (“Evercore”), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively for Shire and no one else in connection with the matters referred to in this announcement and will not regard any other person as its client in relation to the matters referred to in this announcement and will not be responsible to anyone other than Shire for providing the protections afforded to clients of Evercore, nor for providing advice in relation to the matters referred to in this announcement.

Morgan Stanley & Co. International plc, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting as financial adviser to Shire and no one else in connection with the matters referred to in this announcement.  In connection with such matters, Morgan Stanley & Co. International plc, its affiliates and its and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person other than Shire for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.

Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, each in the United Kingdom, is acting as financial adviser to Shire and for no one else in connection with the matters set out in this announcement.  In connection with such matters, Citigroup Global Markets Limited, its affiliates and its and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Shire for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any matter referred to herein.

FORWARD – LOOKING STATEMENTS – “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire’s products may not be a commercial success;
  • revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014;
  • the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire’s products may impact future revenues, financial condition and results of operations;
  • Shire conducts its own manufacturing operations for certain of its Rare Diseases products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in the Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
  • the development, approval and manufacturing of Shire’s products is subject to extensive oversight by various regulatory agencies. Submission of an application for regulatory approval of any of Shire’s product candidates, such as Shire’s planned submission of a New Drug Application to the FDA for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults, may be delayed for any number of reasons and, once submitted, may be subjected to lengthy review and ultimately rejected. Moreover, regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire’s ability to sell or market products profitably.  Fluctuations in buying or distribution patterns by such customers can adversely impact Shire’s revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
  • Shire faces intense competition for highly qualified personnel from other companies, academic institutions, government entities and other organizations. Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire’s ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
  • failure to achieve Shire’s strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire’s financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire’s filings with the US Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

NON GAAP MEASURES

  • The announcement contains financial measures not prepared in accordance with US GAAP.
  • These Non GAAP financial measures are used by Shire’s management to make operating decisions because they facilitate internal comparisons of the Company’s performance to historical results and to competitors’ results. They should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
  • The following items are excluded from these Non GAAP financial measures:
    • Amortization and asset impairments:
      • Intangible asset amortization and impairment charges; and
      • Other than temporary impairment of investments.
    • Acquisitions and integration activities:
      • Upfront payments and milestones in respect of in-licensed and acquired products;
      • Costs associated with acquisitions, including transaction costs, and fair value adjustments on contingent consideration and acquired inventory;
      • Costs associated with the integration of companies; and
      • Non-controlling interest in consolidated variable interest entities.
    • Divestments, re-organizations and discontinued operations:
      • Gains and losses on the sale of non-core assets;
      • Costs associated with restructuring and re-organization activities;
      • Termination costs; and
      • Income / (losses) from discontinued operations.
    • Legal and litigation costs:
      • Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal legal team costs).
  • A reconciliation of these Non GAAP financial measures to the most directly comparable measure under US GAAP can be found within the Investor’s section on Shire’s website at http://www.Shire.com.

CONTACTS

    Media enquiries

    Shire
    Jessica Mann                                                +44 1256 894 280
    Stephanie Fagan                                              +1 201 572 9581

    FTI Consulting (Media Adviser to the Company)
    Andrew Lorenz (London)                                      +44 77 7564 1807
    Ben Atwell (London)                                         +44 20 3727 1000
    David B. Roady (New York)                                    +1 212 850 5600
    Robert Stanislaro (New York)                                 +1 212 850 5600

    Citi (Financial Adviser to the Company)
    Christopher Hite                                             +1 212 816 1818
    Jan Skarbek                                                 +44 20 7986 4000

    Evercore (Financial Adviser to the Company)
    Francois Maisonrouge                                        +44 20 7653 6000
    Edward Banks

    Morgan Stanley (Financial Adviser to the Company)
    Michele Colocci                                             +44 20 7425 8000
    Colm Donlon
    Peter Moorhouse (Corporate Broking)
Friday, June 20th, 2014 Uncategorized Comments Off on (SHPG) Confirms Rejection of AbbVie Proposal

(CARA) and Enteris, Oral Peptide Delivery Tech Enables Acute and Chronic Pain Drug

Cara Therapeutics Initiates Further Phase 1a/1b Trial of Enteris’ Tablet Formulation of Oral CR845 Following Successful Initial Phase 1 Study

BOONTON, N.J., June 20, 2014  — Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (Nasdaq: CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.

The tablet formulation of oral CR845 was formulated utilizing Enteris’ proprietary oral delivery technology under a Manufacturing and Clinical Supply Agreement.  The agreement with Cara Therapeutics is representative of Enteris’ broader “Feasibility-to-Licensing” strategy involving its peptide and small molecule oral drug delivery platform.

Brian Zietsman, President and CFO of Enteris BioPharma, commented, “We are very pleased with the continued progress of oral CR845 as it showcases the potential of Enteris’ proprietary oral delivery technology and the value that we offer to strategic partners.  The advancement of oral CR845 adds to the clinical validation of our oral drug delivery platform, which has been shown to be safe and well tolerated and has demonstrated clinically meaningful efficacy and enhanced bioavailability in Phase 2 and Phase 3 studies conducted by other partners.”

As reported in the prior Phase 1 study, oral CR845 demonstrated a mean oral bioavailability of 16% across all groups under fasting conditions, with peak and total exposures proportional to each dose. Peripheral kappa opioid receptor activation was seen at all doses tested as measured by a standard biomarker. Additionally, orally administered CR845 appeared to be safe and generally well tolerated across all doses tested.

Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics, remarked, “We continue to be very impressed with the bioavailability and bioactivity exhibited by the oral formulation of CR845, and we look forward to reporting top-line pharmacokinetic, safety and biomarker data from our Phase 1a/1b study in the fourth quarter of 2014. In our estimation, oral CR845 has the potential to address a significant market opportunity in the treatment of acute and chronic pain for which there continues to be a very large unmet need for safer, non-abusable alternatives to narcotic opioids and NSAIDs.”

About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. Enteris’ proprietary oral delivery technology has demonstrated a track record of success across a range of compounds and therapeutic indications and has also been the subject of numerous feasibility studies and active development programs, several of which are in advanced stages of clinical development. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.

For Enteris BioPharma:            Media Contacts:
Tim Saxon Jason Rando / Claire Sojda
973.453.3515 Tiberend Strategic Advisors, Inc.
tsaxon@enterisbiopharma.com 212.827.0020
jrando@tiberend.com
csojda@tiberend.com
Friday, June 20th, 2014 Uncategorized Comments Off on (CARA) and Enteris, Oral Peptide Delivery Tech Enables Acute and Chronic Pain Drug

(CBMG) Announces Closing of $10 Million Private Placement Offering

PALO ALTO, Calif., June 20, 2014  — Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the “Company”), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to selected private investors (the “Investors”) at $6.70 per share, for total gross proceeds of approximately $10 Million.

The Investors were led by veteran Hong Kong investment banker Mr. Francis Leung, who stated, “I am looking forward to working with CBMG’s management team in realizing their vision of leveraging cell technology to improve people’s lives. I am committed to the Company and confident that their clinical trials will eventually benefit millions of people in China and abroad.”

Mr. Leung has over 30 years of experience in investment banking, in particular, the field of corporate finance involving capital raising, mergers and acquisitions, corporate restructuring and other general financial advisory activities, and principal investments in Hong Kong and the PRC. He is currently the Chairman (Greater China) and a managing partner of CVC Asia Pacific. On a personal basis, Mr. Leung is a seasoned growth capital investor.

Net proceeds from the financing will be primarily used for ongoing clinical trials, working capital and potential acquisitions of strategic assets.

For a complete description of the private placement and all related documents, please refer to the Company’s Form 8-K that will be filed in connection with the transaction.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         vivian.chen@grayling.com
Friday, June 20th, 2014 Uncategorized Comments Off on (CBMG) Announces Closing of $10 Million Private Placement Offering

(RBY) Construction of the Phoenix Gold Project Continues on Schedule and on Budget

TORONTO, ONTARIO–(Jun 19, 2014) – Rubicon Minerals Corporation (TSX:RMX)(NYSE MKT:RBY) (“Rubicon” or the “Company“) has substantially advanced the Phoenix Gold Project (“Project“), with project construction and development remaining on budget and on schedule for projected production in mid-2015.

“We are pleased with the progress of the construction and de-risking of the Phoenix Gold Project,” said Michael A. Lalonde, President and Chief Executive Officer of Rubicon. “The Project is tracking to schedule and budget compared to the targets we had set earlier this year. We will continue to closely monitor our activities and associated capital costs as the Project progresses toward the projected operating phase in mid-2015.”

The Phoenix Gold Project Development and Construction Update

Underground Project Development and Construction

Advance rates on both the lateral and vertical development have been tracking on schedule. Rubicon has completed 875 metres of a planned 8,023 metres (or 10.9%) of total underground development (lateral and vertical) at and above the 685-metre level. The completion of this planned underground development is required to commence projected production. The Company continues lateral development at the 122-, 183-, 244-, 305-, 610-, and 685-metre levels. The 244- and 305-metre levels were previously advanced to the deposit, prior to the completion of shaft sinking. An exploration drift on the 244-metre level is progressing well, with 13 drill stations completed of a planned 18 stations. There are two drills currently operating on the level. The development of the main ventilation pilot raise from the 305-metre level to surface will be completed by the end of June. At the present time, all underground development is being carried out by a contractor. Rubicon is in the process procuring equipment and hiring staff to replace the majority of the contractors engaged in lateral development, which could potentially lower costs and increase productivity. A summary of the total underground development is displayed in Figure 1.

The Company has secured favourable lease terms for all of its underground equipment needs. The lease terms are 4.5% over a 5-year term, with a 10% down payment. The lease will cover $15.0 million of mobile equipment purchases over the next two years, or 25 units. The initial fleet of mobile equipment has started to arrive on site, and is being commissioned.

The Company has approximately $42.0 million (as at May 31, 2014) of total underground development capital remaining to the start of potential production.

Mill Construction

Full mill construction recommenced on April 1, 2014, with civil works in the mill building continuing. Civil, process, and electrical engineering for the mill is approximately 81.0% complete. The Elution plant, which extracts gold from the carbon in the leaching process, is near completion. The equipment for the Elution plant has been installed, with the piping and electrical work remaining to be completed. The formation of the tank bases, pump bases, containment areas and pillars have been completed. Concrete will soon be poured in the mill thickener area, just outside the mill building.

Rubicon has approximately $71.5 million (as at May 31, 2014) of mill capital expenditures remaining to completion. Mill construction is on track to be completed and commissioned by mid-2015.

Surface Infrastructure and On-Site Construction

The Actiflo system, which will be the final stage of effluent water treatment, has been fully commissioned. The raw ore bin has been installed in the head frame. The construction of the tailings management facility, which was halted during the winter months, has resumed and is near completion. Rubicon has approximately $31.7 million (as at May 31, 2014) of on-site construction remaining to completion.

See figures 2, 3, 4 for the pictures of the construction and development progress of the Phoenix Gold Project. For more pictures of the Project construction and development progress, please visit our website at http://www.rubiconminerals.com/Investors/Photo-Galleries/default.aspx.

Pre-Production Capital and Timeline to Potential Production

As of May 31, 2014, Rubicon estimates that pre-production capital to complete the Project is $167.5 million, including contingency. A breakdown of the capital expenditures remaining can be seen in Table 1. Rubicon has approximately $180 million in cash and cash equivalents on its balance sheet to date and anticipates it will receive the US$45 million remaining on the Royal Gold streaming transaction over the next several quarters, as spending on construction and development increases. The construction of the Phoenix Gold Project remains on schedule and on budget. The timeline to projected production remains mid-2015.

Table 1: Capital Expenditures Remaining as of May 31, 2014
Project capex spent, October 1, 2011 to May 31, 2014 C$205.2 million
Remaining capex to projected production
Mill C$71.5 million
Underground development C$42.0 million
On-site construction C$31.7 million
Indirects & definition drilling C$22.3 million
Total remaining capex to projected production (with contingency) C$167.5 million

Aboriginal Communities

The Waubaskang First Nation’s (“WFN”) application for judicial review of the Production Closure Plan for the Phoenix Gold Project was heard by the Ontario Divisional Court between April 15th and 17th. The timeline for a decision was not provided. This application has not impacted construction and development activities at the Phoenix Gold Project. Rubicon continues to believe that the WFN application is without merit and will vigorously defend its position.

To view Figures 1-4, click on the following link: http://media3.marketwire.com/docs/952915f.pdf

About Rubicon Minerals Corporation

Rubicon Minerals Corporation is an advanced stage gold development company. The Company is focused on responsible and environmentally sustainable development of its Phoenix Gold Project in Red Lake, Ontario. The start of potential gold production is projected in mid-2015, based on current forecasts. The Phoenix Gold Project is fully permitted for initial production at 1,250 tonnes per day. In addition, Rubicon controls over 100 square miles of prime exploration ground in the prolific Red Lake gold district which hosts Goldcorp’s high-grade, world class Red Lake Mine. Rubicon’s shares are listed on the NYSE MKT (RBY) and the Toronto Stock Exchange (RMX).

RUBICON MINERALS CORPORATION

Mike Lalonde, President and Chief Executive Officer

The content of this news release has been read and approved by Daniel Labine, P.Eng., Vice President of Operations and Mark Ross, B.Sc., P.Geo., Chief Mine Geologist, for Rubicon. Both are Qualified Persons as defined by NI 43-101.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements” within the meaning of Section 21E of the United States Securities Exchange Act of 1934 and “forward looking information” within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting”, “look forward” and “intend” and statements that an event or result “may”, “will”, “would”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and represent management’s best judgment based on facts and assumptions that management considers reasonable. The material assumptions upon which such forward-looking statements are based include, among others; that the demand for gold and base metal deposits will develop as anticipated; that the price of gold will remain at levels that will render the Phoenix Gold Project economic; that operating and capital plans will not be disrupted by issues such as mechanical failure, unavailability of parts and supplies, labour disturbances, interruption in transportation or utilities, or adverse weather conditions; that Rubicon will meet its estimated timeline for the development of the Phoenix Gold Project; that Rubicon will continue to have the ability to attract and retain skilled staff; that the mineral resource estimate as disclosed in the New Preliminary Economic Assessment with an effective date of June 25, 2013 and with an issue date of February 28, 2014 (“New PEA”) will be realized; and that there are no material unanticipated variations in the cost of energy or supplies, or in the pre-production capital and operating cost estimate as disclosed in the New PEA. Rubicon makes no representation that reasonable business people in possession of the same information would reach the same conclusions.

Capital expenditures and time required to develop new mines are considerable and changes in cost or construction schedules can significantly increase both the time and capital required to build and complete a development project. Additional capital costs may be to be incurred in respect of the Phoenix Gold Project.

The New PEA is preliminary in nature as it includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves and there is no certainty that the New PEA will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. The quantity and grade of reported inferred resources referred to in the New PEA are uncertain in nature and there has been insufficient exploration to define these inferred resources as an indicated or measured mineral resource category.

Forward-looking statements in this news release include, but are not limited to statements regarding potential production and the projected timing of the completion of certain construction activities associated with the Phoenix Gold Project.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Rubicon to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: future prices of gold and other metals; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; actual results of reclamation activities; conclusions of future economic evaluations; changes in project parameters as plans continue to be refined; failure of equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays and other risks related to joint venture operations; timing and receipt of regulatory approvals of operations; the ability of Rubicon and other relevant parties to satisfy regulatory requirements; the availability of financing for proposed transactions and programs on reasonable terms; the ability of third-party service providers to deliver services on reasonable terms and in a timely manner; and delays in the completion of development or construction activities. Other factors that could cause the actual results to differ include market prices, results of exploration, availability of capital and financing on acceptable terms, inability to obtain required regulatory approvals, unanticipated difficulties or costs in any rehabilitation which may be necessary, market conditions and general business, economic, competitive, political and social conditions.

It is important to note that the information provided in this news release is preliminary in nature. There is no certainty that a potential mine will be realized. A mine production decision that is made without a bankable feasibility study carries additional potential risks which include, but are not limited to, the inclusion of inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mine design and mining schedules, metallurgical flow sheets and process plant designs may require additional detailed work to ensure satisfactory operational conditions.

Forward-looking statements contained herein are made as of the date of this news release and Rubicon disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Cautionary Note to U.S. Readers Regarding Estimates of Indicated and Inferred Resources

This news release uses the terms “indicated mineral resources” and “inferred resources”. The Company advises U.S. investors that while these terms are recognized and required by Canadian securities administrators, they are not recognized by the SEC. “Inferred resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an “inferred” or “indicated mineral resource” will ever be upgraded to a higher category.

Under Canadian rules, estimates of “inferred mineral resources” may not form the basis of feasibility studies, pre-feasibility studies or other economic studies, except in prescribed cases, such as in a preliminary economic assessment under certain circumstances. The SEC normally only permits issuers to report mineralization that does not constitute “reserves” as in-place tonnage and grade without reference to unit measures. Under U.S. standards, mineralization may not be classified as a “reserve” unless the determination has been made that the mineralization could be economically and legally produced or extracted at the time the reserve determination is made. U.S. investors are cautioned not to assume that any part or all of an indicated or inferred resource exists or is economically or legally mineable. Information concerning descriptions of mineralization and resources contained herein may not be comparable to information made public by U.S. companies subject to the reporting and disclosure requirements of the SEC.

Mineral Resources

Mineral resources that are not mineral reserves do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. The quantity and grade of reported inferred resources in this estimation are uncertain in nature and there has been insufficient exploration to define these inferred resources as an indicated or measured mineral resource and it is uncertain if further exploration will result in upgrading them to an indicated or measured mineral resource category. The mineral resources in this press release were reported using CIM Standards.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Rubicon Minerals Corporation
Allan Candelario
Director of Investor Relations
1.866.365.4706
ir@rubiconminerals.com
www.rubiconminerals.com

Thursday, June 19th, 2014 Uncategorized Comments Off on (RBY) Construction of the Phoenix Gold Project Continues on Schedule and on Budget

(PZG) New Resource Estimate and PEA Expected for San Miguel Project in Mexico

Resource Estimate expected in July 2014 followed by PEA in August 2014

WINNEMUCCA, NEVADA–(June 19, 2014) – Paramount Gold and Silver Corp. (TSX:PZG)(NYSE MKT:PZG)(FRANKFURT:P6G)(WKN:A0HGKQ) (“Paramount”) announced today that its independent consultants are nearing completion of a new NI-43-101 compliant resource estimate for its 100%-owned San Miguel Project in Northern Mexico to be followed by a revised Preliminary Economic Assessment (PEA) for the project. A PEA is a complete, integrated project design which estimates mining and processing methods and rates of production, capital and operating costs, cash flows at specified metal prices, rates of return, mine life and net present values at a proposed discount rate.

Mine Development Associates (“MDA”) (www.mda.com) of Reno, Nevada is currently preparing the new resource estimate to incorporate the results of drill holes within the resource areas since the last estimate prepared in September 2012. The updated resource estimate is expected to materially upgrade resources from the inferred classification to measured and indicated classifications as well as increase the overall size of the resource.

A revised PEA for the San Miguel project will follow the completion of the resource estimate, once again prepared by Metal Mining Consultants (“MMC”) (www.metalminingconsultants.com) of Denver, Colorado. The revised Mine Plan will incorporate: the new resource estimate; current gold/silver prices; a heap leach scenario for the San Francisco and San Antonio zones; and a reconfigured model using smaller ore blocks.

The new heap leach scenario at San Francisco and San Antonio is the result of the Company’s foresight to evaluate material which was not included in the previous mill-only PEA scenario. The metallurgical work completed by McClelland Laboratories of Reno, NV confirmed that heap leaching this material is a likely scenario (see news release May 27, 2014) and could increase estimated resources, mine life and project economics.

Paramount CEO Christopher Crupi exclaimed, “We are eager to see the results of the updated resource and mine plans for San Miguel. We anticipate they will demonstrate the potential for a strong, economically-rewarding project at current metal prices.”

NI 43-101 Disclosure

Exploration activities at San Miguel are being conducted by Paramount Gold de Mexico S.A de C.V personnel under the supervision of Glen van Treek, Exploration Vice President of the Company and Bill Threlkeld, a Qualified Person as defined by National Instrument 43-101, who have both reviewed and approved this press release. An ongoing quality control/quality assurance protocol is employed including blank, duplicate and reference standards in every batch of assays. Cross-check analyses are conducted at a second external laboratory on 10% of the samples. Samples are assayed at ALS Chemex and Acme Laboratories, Vancouver, B.C., using fire assay atomic absorption methods for gold and aqua regia digestion ICP methods for other elements.

Cautionary Note to U.S. Investors Concerning Estimates of Indicated and Inferred Resources

This news release uses the terms “measured and indicated resources” and “inferred resources”. We advise U.S. investors that while these terms are defined in, and permitted by, Canadian regulations, these terms are not defined terms under SEC Industry Guide 7 and not normally permitted to be used in reports and registration statements filed with the SEC. “Inferred resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Under Canadian rules, estimates of inferred mineral resources may not form the basis of a feasibility study or prefeasibility studies, except in rare cases. The SEC normally only permits issuers to report mineralization that does not constitute SEC Industry Guide 7 compliant “reserves”, as in-place tonnage and grade without reference to unit measures. U.S. investors are cautioned not to assume that any part or all of mineral deposits in this category will ever be converted into reserves. U.S. investors are cautioned not to assume that any part or all of an inferred resource exists or is economically or legally minable.

Safe Harbor for Forward-Looking Statements:

This release and related documents may include “forward-looking statements” including, but not limited to, statements related to the expected new resources estimate and PEA for the San Miguel Project and the expected results of this work, estimates of resources including expected volumes and grades and the economic projections included in the project’s PEA and the results of metallurgical testing. Forward-looking statements are statements that are not historical fact and are subject to a variety of risks and uncertainties which could cause actual events to differ materially from those reflected in the forward-looking statements including fluctuations in the price of gold, inability to complete drill programs on time and on budget, and future financing ability. Paramount’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Words such as “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to: uncertainties involving interpretation of drilling results, environmental matters, lack of ability to obtain required permitting, equipment breakdown or disruptions, and the other factors described in Paramount’s Annual Report on Form 10-K for the year ended June 30, 2013 and its most recent quarterly reports filed with the SEC.

Except as required by applicable law, Paramount disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this document.

Paramount Gold and Silver Corp.
Glen Van Treek
VP Exploration
866-481-2233

Paramount Gold and Silver Corp.
Chris Theodossiou
Investor Relations
866-481-2233

Thursday, June 19th, 2014 Uncategorized Comments Off on (PZG) New Resource Estimate and PEA Expected for San Miguel Project in Mexico

(ALDX) Appoints Stephen Tulipano Chief Financial Officer

BURLINGTON, Mass., June 19, 2014  — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Stephen Tulipano has joined Aldeyra as its Chief Financial Officer, effective June 23, 2014. Mr. Tulipano will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.

“We are excited to have Steve join Aldeyra, as he brings to the Company a strong financial background and significant experience in the pharmaceutical industry,” said Dr. Brady. “Given his proven track record of managing a company’s finances during clinical trials, Steve will be a tremendous asset as we advance the clinical development of our lead product candidate, NS2, for the treatment of Sjogren-Larsson Syndrome and acute anterior uveitis. We look forward to working with Steve as we continue to pursue a safe and effective treatment option for diseases related to free aldehydes.”

Mr. Tulipano has nearly 27 years of accounting and financial experience, of which 12 years were focused on the pharmaceutical industry. Most recently, he held positions at Three Tulips Inc., an accounting and management advisory services firm, where he provided full-time accounting services and financial management counsel. Prior to that, he served as Chief Financial Officer of Javelin Pharmaceuticals where he helped lead the company through its acquisition by Hospira in 2010.  Previously, he held the role of Director of Corporate Accounting at Biogen Idec, one of the oldest biopharmaceutical companies in the U.S. He has also held several accounting roles both within companies and accounting firms.

Mr. Tulipano commented, “Joining the Aldeyra team is a great opportunity to be part of an accomplished management team that is pursuing a novel drug platform to treat both orphan and mass-market diseases. I believe my previous experience in financial accounting within the pharmaceutical industry positions me well in this role and I look forward to contributing to the Company’s growth and long-term success.”

Mr. Tulipano holds a B.S. in Business Administration and Accounting from Salem State College and an M.B.A. in Finance from the Sawyer School of Management at Suffolk University. He is also a Certified Public Account.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; the size and growth of the potential markets for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and revenue, the sufficiency of Aldeyra’s cash resources and needs for additional financing; Aldeyra’s ability to attract or retain key personnel; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s final prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission (SEC) in connection with Aldeyra’s initial public offering and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the SEC on June 11, 2014. In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Investor Contact:
         David Burke/Lee Roth
         The Ruth Group
         Tel: +1 646-536-7009/7012
         dburke@theruthgroup.com/lroth@theruthgroup.com
Thursday, June 19th, 2014 Uncategorized Comments Off on (ALDX) Appoints Stephen Tulipano Chief Financial Officer

(SCOK) Issues Update on Construction of New Syngas Facility

PINGDINGSHAN, CHINA–(Jun 19, 2014) – SinoCoking Coal and Coke Chemical Industries, Inc. (NASDAQ: SCOK) (“the Company” or “SinoCoking”), a vertically-integrated coal and coke processor, today announced that construction of the initial phase of its environmentally-friendly facility for the conversion of carbon dioxide into a clean-burning synthetic gas (syngas) has been completed. The facility is currently on target to begin operations and produce syngas in the fourth quarter of this calendar year.

SinoCoking Chairman and CEO Mr. Jianhua Lv said, “This facility, once operational will be one of the largest of its kind in China. We have currently commenced the installation of gas furnaces, electrical equipment and consoles, as well as transporting system, dust removal system, and cooling and purification system.”

Mr. Lv continued, “These installations are expected to be completed within 30 days and will be followed by a 60-day adjustment and calibration period. Once completed, the facility is expected to commence initial production of syngas.”

Construction of the facility involves over 160 workers and is being managed by Lin Yu Jian Group, a major engineering contracting company based in Henan province. As previously announced, the facility is expected to produce 25,000 cubic meters of syngas per hour. The gross profit margin on syngas sales is expected to be between 45% and 50%, far higher than any other current SinoCoking product.

“We are very excited by our rapid construction progress,” continued Mr. Lv. “This facility can potentially provide SinoCoking with new streams of high-margin revenue. Additionally, we will be providing China with significant quantities of a clean-burning fuel which, as China’s President Xi Jinping urged, should be replacing coal as an energy source.”

On June 16, 2014, China president Xi Jinping called for an “energy revolution” to address the nation’s soaring energy demands, crippling pollution problems and massive greenhouse gas emissions. Chinese authorities are enforcing new regulations designed to control these conditions, including placing greater focus on clean coal technologies.

Mr. Lv concluded, “SinoCoking stands ready to cooperate with President Xi’s program to make China’s atmosphere cleaner and healthier with an abundant source of clean energy. We look forward to providing additional details on the progress made to complete the construction of our syngas facility.”

About SinoCoking
SinoCoking and Coke Chemical Industries, Inc., a Florida corporation, is a vertically-integrated coal and coke processor that uses coal from both its own mines and that of third-party mines to produce basic and value-added coal products for steel manufacturers, power generators, and various industrial users. SinoCoking has been producing metallurgical coke since 2002, and acts as a key supplier to regional steel producers in central China. SinoCoking also produces and supplies thermal coal to its customers in central China. SinoCoking currently owns its assets and conducts its operations through its subsidiaries, Top Favour Limited and Pingdingshan Hongyuan Energy Science and Technology Development Co., Ltd., and its affiliated companies, Henan Province Pingdingshan Hongli Coal & Coke Co., Ltd., Baofeng Coking Factory, Baofeng Hongchang Coal Co., Ltd., Baofeng Hongguang Environment Protection Electricity Generating Co., Ltd., Zhonghong Energy Investment Company, Henan Hongyuan Coal Seam Gas Engineering Technology Co., Ltd., Baofeng Shuangrui Coal Mining Co., Ltd., and Baofeng Xingsheng Coal Mining Co., Ltd.

For further information about SinoCoking, please refer to our periodic reports filed with the Securities and Exchange Commission.

Forward Looking Statement
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place undue reliance on such statements. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may differ materially from the Company’s expectations and estimates. The Company provides no assurances that any potential acquisitions will actually be consummated, or if consummated that such acquisitions will be on terms and conditions anticipated on the date of this press release, and the Company makes no assurances with regard to any results of any such acquisitions.

Contact:
SinoCoking
Song Lv
Chief Financial Officer
+ 86-375-2882-999
Email Contact
www.scokchina.com

Investor Relations Counsel:
Lena Cati
The Equity Group Inc.
(212) 836-9611
Email Contact
www.theequitygroup.com

Thursday, June 19th, 2014 Uncategorized Comments Off on (SCOK) Issues Update on Construction of New Syngas Facility

(CBMG) Positive Six-Month Data Phase I/IIa on ReJoin™ in Knee Osteoarthritis

Patient Cartilage Regrowth Within Three Months

PALO ALTO, Calif., June 19, 2014  — Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin™ human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.

The primary endpoints for this trial were safety and knee-related pain, stiffness and function measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. The secondary endpoints were cartilage repair at six months, defined through the volume of the repair tissue measured with quantitative magnetic resonance imaging (MRI) as well as NRS-11, SF-36 and KSCRS scores.

With the last patient treated in Q4 2013, analysis of the full six-month follow-up data has revealed:

  • MRI Quantitative Assessment: Increase in cartilage volume of whole joint as early as three months after the therapy, and confirmed average of 53.07mm3 six months after the therapy. Reduction of bone marrow lesions in some patients.
  • Western Ontario and McMaster Universities Arthritis Index (WOMAC): Decreased by 14.69 from the baseline (P<0.01); improved knee mobility
  • Numeric Rating Scale for Pain (NRS-11): Decreased by 2.35 from the baseline (P<0.01); significantly reduced knee pain
  • Short Form Health Survey (SF-36): Decreased by 4.69 from the baseline (P>0.05)
  • Knee Society Clinical Rating System (KSCRS): Increased by 29.38 from the baseline (P<0.01); prolonged walking distance
  • No serious adverse events (SAE)

“We are very excited that the data from this trial has surpassed our expectations. Patients have reported a significant improvement in mobility, flexibility and a decrease in pain, while the clinical data shows ReJoinTM therapy to be both safe and effective. We look forward to reviewing the 12-month follow-up data in Q4 of this year,” commented Wei (William) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group, Inc. “The opportunity for patients to regenerate their damaged knee cartilage using their own stem cells, could be much more preferable to undergoing painful, invasive knee replacement surgery or other invasive surgery procedures. In addition to the potential to improve quality of life for many patients, the positive results from the ReJoinTM trial represent a rapid pathway for us to begin commercializing this therapy in China, in what we believe is the largest KOA market in the world.”

Knee Osteoarthritis in China

According to International Journal of Rheumatic Diseases, 2011 there are approximately 57 million people in China suffering from knee osteoarthritis. Drug-based methods of management to date are ineffective, the quality of life of patients with KOA is compromised, and many KOA patients will degenerate to the point of requiring invasive artificial joint replacement surgery. According to Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257) 53% of KOA patients will eventually become disabled.

About ReJoinTM Therapy

Cellular Biomedicine Group’s ReJoinTM therapy for KOA is an interventional therapy that consists of 30ml of adipose (fat) tissue obtained via lipoaspiration from the patient, from which the patient’s vascular stromal cells (VSC; a combination of several types of monocytes including mesenchymal stem cells) are isolated using CBMG’s proprietary medical device, the A-Stromal Kit, which produces a high yield of VSC, and haMPCs are then expanded using CBMG’s proprietary culture medium. After three weeks there is an initial injection into the knee joints and a second injection three weeks later.

Some of the special characteristics of ReJoinTM Therapy are:

  • Autologous – patient’s own cells
  • Readily available, easy to source via minimally invasive lipoaspirate
  • Unlimited supply of own cells from one lipoaspirate
  • No immune rejection
  • High concentration of stem cells – only 30ml of adipose (fat) tissue required
  • Shortest time to profound results, including cartilage regrowth
  • Quick recovery relatively compared to knee replacement surgery
  • Long term therapeutic effects
  • No severe side effects

Cellular Biomedicine Group is currently running a multi-center Phase IIb clinical trial for ReJoinTM, which further studies the efficacy of CBMG’s proprietary haMPC-based therapy for KOA.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         vivian.chen@grayling.com
Thursday, June 19th, 2014 Uncategorized Comments Off on (CBMG) Positive Six-Month Data Phase I/IIa on ReJoin™ in Knee Osteoarthritis

(STEM) Results Show Improvement in Visual Function Phase I/II Dry AMD Trial

Company to Host Webcast to Discuss Interim Data Today

NEWARK, Calif., June 19, 2014  — StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company’s proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.

  • Interim trial results show a 65 percent reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 percent reduction in the rate of GA when compared to the control eye.
  • GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium. This degeneration is the cause of vision loss in dry AMD.
  • Interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark, also referred to as “contrast sensitivity.”
  • Contrast sensitivity was improved in four of the seven patients and remained stable in the other three patients.
  • The interim analysis is based on a minimum follow up of at least 6 months and demonstrates a favorable safety profile for administration of the HuCNS-SC cells into the sub-retinal space of the study eye.

“The interim data are very encouraging from two separate perspectives. First, the reduction in the rate of geographic atrophy suggests the HuCNS-SC cells are affecting the underlying cause of AMD. Secondly, the data demonstrates there are increases in contrast sensitivity, which is a vital aspect of visual function,” said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research and chief medical officer at StemCells, Inc. “Impacting the progression of GA and enhancing visual function could have a very meaningful impact on the quality of life for AMD patients and the results to date strongly support our plans to initiate a randomized, controlled, Phase II proof-of-concept trial later this year.”

“These interim results have exceeded our expectations at this stage of the trial,” said David Birch, Ph.D., chief scientific and executive officer of the Retina Foundation of the Southwest in Dallas, Texas. “These results are particularly interesting given that the first cohort of patients had significant visual impairment and baseline GA. The next cohort of patients will have less impairment and we look forward to learning even more as we analyze data from the patients in the second half of the trial.”

StemCells, Inc. will host a conference call and webcast to discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD, after market close today, Thursday, June 19, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time).

Interested parties are invited to listen to the call over the Internet by accessing the Investors section of the Company’s website at www.stemcellsinc.com. Webcast participants should allot extra time before the webcast begins to register and, if necessary, download and install audio software.

Event: Interim Results from the StemCells, Inc. Phase I/II clinical trial in dry AMD

Date: Thursday, June 19, 2014

Time: 4:30 PM EDT (1:30 PM PDT)

Live webcast: http://www.media-server.com/m/acs/113baab16d15da4dd0c81018d65a272e

An archived version of the webcast will be available for replay on the Company’s website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days.

About Age-Related Macular Degeneration and Geographic Atrophy

An estimated 10 million people in the United States either have age-related macular degeneration (AMD) or are at substantial risk for receiving the diagnosis, according to the Foundation Fighting Blindness. AMD, a degenerative retinal disease that typically strikes adults in their 50s or early 60s and gradually progresses to destroy central vision, is the leading cause of blindness in adults over 55 years of age in the developed world. Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. Approximately 85-90 percent of AMD cases are the “dry” type of the disease, the advanced form of which is referred to as “geographic atrophy.”

About the Trial

The Phase I/II trial evaluates the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. Patients with dry AMD had to have evidence of GA to be eligible for inclusion. The investigation is divided into two sequential cohorts. Subjects are enrolled into each cohort based on best-corrected visual acuity (BCVA), as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. Patients with BCVA of less than or equal to 20/400 in the study eye were enrolled in Cohort I. Patients with less severe BCVA of 20/320 to 20/100 in the study eye are being enrolled in Cohort II. Cohort I consists of four subjects who were each transplanted with 200,000 stem cells, followed by four subjects who have each been transplanted with 1 million cells. Cohort II will consist of eight subjects who will undergo transplant with 1 million cells. The HuCNS-SC cells are administered by a single injection into the space behind the retina in the most affected eye. Patients’ vision is being evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations are being performed at predetermined intervals over a one-year period to assess safety and signs of vision improvement. Patients will be followed for an additional four years in a separate observational study.

The trial enrolled at five locations:

  • Retina Foundation of the Southwest, Dallas, Texas
  • Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA
  • New York Eye and Ear Infirmary, New York, NY
  • Retina Research Institute of Texas, Abilene, TX
  • Retina-Vitreous Associates Medical Group, Los Angeles, California

More information about the StemCells Dry Age Related Macular Degeneration program can be found on the Company website at: http://www.stemcellsinc.com/Therapeutic-Programs/AMD-and-Retinal-Disorders.htm

Additional information about the clinical trial is available at: http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at the U.S. National Institutes of Health website at: http://www.clinicaltrials.gov/ct2/show/NCT01632527?term=stemcells+inc+amd&rank=1

About HuCNS-SC Cells

StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies of its proprietary HuCNS-SC cells. StemCells clinicians and scientists believe that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the central nervous system (CNS). Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. The Company’s preclinical research established that HuCNS-SC cells can be directly transplanted in the CNS with no sign of tumor formation or adverse effects. The HuCNS-SC platform technology is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s platform technology, HuCNS-SC® cells (purified human neural stem cells), is currently in clinical development as a potential treatment for a broad range of central nervous system disorders. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. In addition, the Company is pursuing preclinical studies in Alzheimer’s disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of the Company’s HuCNS-SC cells to preserve vision; the prospect and timing of patient enrollment in the Company’s clinical trial in dry AMD; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA or other applicable regulatory agencies or review boards will permit the Company to continue clinical testing in AMD; uncertainties regarding the timing and duration of any clinical trials; uncertainties regarding the Company’s ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128

         Andrea Flynn
         Russo Partners
         (646) 942-5631
Thursday, June 19th, 2014 Uncategorized Comments Off on (STEM) Results Show Improvement in Visual Function Phase I/II Dry AMD Trial

(ADBE) Announces All New 2014 Release of Creative Cloud

Adobe (Nasdaq:ADBE), the leader in creative software, today continued to drive Creative Cloud innovation by announcing 14 new versions of CC desktop applications, including essential tools such as Adobe Photoshop CC, Adobe Illustrator CC, Adobe Dreamweaver CC and Adobe Premiere Pro CC. The biggest Adobe software release since CS6, it also includes four new mobile apps, the immediate availability of creative hardware, updates to Creative Cloud services and new offerings for enterprise, education and photography customers. Yesterday, Adobe announced that there are now over 2.3 million Creative Cloud subscriptions, far exceeding original projections when it was unveiled two years ago.

Adobe Ink & Slide (Photo: Business Wire)

“Our shift to Creative Cloud has given us a broad canvas on which to innovate like never before,” said David Wadhwani, senior vice president, Digital Media, Adobe. “We’ve taken bold steps with this milestone release, fast-tracking new features to industry-defining tools like Photoshop and InDesign, while introducing mobile apps that turn tablets into indispensable creative tools.”

The release serves a creative industry that is changing at a staggering pace: three in four creatives believe the industry has changed more in the past five years than the previous 50 and about two thirds believe their role will significantly change in the next 3 years (see The New Creatives Report, surveying 1,000 U.S. creatives, issued June 16). Creatives cited new technologies as the top driving force behind the rapid change.

Mobile Apps Extend CC Desktop Workflows

Delivering on mobile innovation, Adobe launched three new mobile apps for iPad – Adobe Sketch, Adobe Line, and Adobe Photoshop Mix; and began shipping new creative hardware called Adobe Ink, a new digital pen, and Adobe Slide, a new digital ruler (see separate release). The mobile apps were developed using a new Adobe Creative SDK that unlocks over 30 years of Adobe innovation and makes it available on mobile devices for the first time. These new apps are professional-grade quality but easy enough for anyone to use, similar to the recently launched Lightroom mobile for photographers and Adobe’s new animated video app for storytelling, Adobe Voice, which were also updated with this release. These powerful, yet easy-to-use apps add significant mobile capabilities to Creative Cloud, integrate workflows with the CC desktop apps and bring tablets into serious creative workflows for the first time.

New Versions of CC Desktop Apps

Beyond mobile innovation, the 2014 release of Creative Cloud delivers more Adobe magic, makes everyday tasks easier and faster, while delivering new support for cutting-edge hardware and standards. Highlights of top features in the 14 new desktop apps include:

  • New capabilities in Photoshop CC for photographers such as, Blur Gallery motion effects for creating a sense of motion; Focus Mask that makes portrait shots with shallow depth of field stand out; new Content-Aware capabilities; and the recently introduced Perspective Warp for fluidly adjusting the perspective of a specific part of your image without affecting the surrounding area. Designers using Photoshop CC will enjoy enhanced Mercury Graphics Engine performance as well as the ability to link Smart Objects and share them across multiple documents. With improved Layer Comps, users save time by changing the visibility, position, or appearance of one layer and simply syncing to see the change reflected in all other Layers. Photoshop CC also has ability to pinch and zoom images, create smoother strokes, and deliver a more responsive experience on Windows 8 Touch devices, such as Microsoft Surface Pro 3.
  • Also for designers, new capabilities in Illustrator CC include Live Shapes to quickly transform rectangles into complex shapes and then return to the original rectangle with just a few clicks, as well as faster rendering of vector graphics with GPU acceleration on Windows with an Adobe-certified NVIDIA graphics card. In InDesign CC, layout artists can now select table rows and columns and use EPUB Fixed Layout to easily create digital books. Adobe Muse CC now includes 64-bit support, HiDPI display support for sharper-looking images, objects, and text, and the ability to preview and optimize desktop, smartphone and tablet versions of your sites before going live.
  • New features in the video apps include, Live Text Templates and Masking and Tracking, new integrations that leverage the power of Adobe After Effects CC inside Adobe Premiere Pro CC. Race through projects thanks to enhanced graphics performance in Premiere Pro; precise new keying effects in After Effects; a more flexible Direct Link color pipeline in Adobe SpeedGrade CC; and enhanced multi-track tools for audio work in Adobe Audition CC. Integration between apps has also been further improved to save time when working between Premiere Pro and After Effects or SpeedGrade.
  • Web tools now include the ability to look at the markup in a document using the new Element Quick View in Dreamweaver CC, which allows Web developers to easily see, navigate, and modify the HTML structure of pages. CSS Designer improvements help apply CSS properties like gradients, box shadows and borders and then easily undo. SVG export in Flash Pro CC lets developers export any frame in Flash projects as an SVG file, while native HTML video support in Edge Animate CC allows the direct import of HTML5-friendly video clips.

Your Creative Assets and Your Creative Profile Anywhere

The new CC desktop apps, mobile apps, and hardware are tightly integrated through Creative Cloud services. This integration helps liberate the creative process by enabling users to access and manage everything that makes up their creative profile – their files, photos, fonts, colors, community and more – from wherever they work. Also introduced today is the new Creative Cloud app for iPhone and iPad that allows users to access and manage their files, assets, and more from their mobile device.

New Creative Cloud Offerings For Enterprises, Educational Institutions and Photographers

Adobe Creative Cloud for enterprise is an offering designed specifically for large-scale software deployments that works with other Adobe enterprise offerings such as Adobe Marketing Cloud, Acrobat, Adobe Anywhere, and Adobe Digital Publishing Suite. Updates include more services with collaboration and file storage, expanded options for deployment, and a new dashboard for managing users and entitlements. For education, Adobe now has a device-based licensing offer for classrooms and labs, which allows multiple users to access software on a single device rather than tying it to an individual with an Adobe ID, critical in an environment where students come and go. And for photography customers, Adobe has introduced a new Creative Cloud Photography Plan for $9.99 per month (see separate press release).

Pricing and Availability

Today’s updates to CC desktop tools are immediately available for download by Creative Cloud members as part of their membership at no additional cost. The new mobile apps are free to everyone. To join Creative Cloud, special promotional pricing is available to existing customers who own Adobe Creative Suite 3 or later. Membership plans are available for individuals, students, teams, educational institutions, government agencies and enterprises. To download free trials of any of the new Creative Cloud desktop apps, go to: https://www.adobe.com/creativecloud/catalog/desktop.html. For pricing details, visit: https://www.adobe.com/creativecloud.html#buy.

About Adobe Systems Incorporated

Adobe is changing the world through digital experiences. For more information, visit www.adobe.com.

© 2014 Adobe Systems Incorporated. All rights reserved. Adobe, the Adobe logo, Acrobat, Creative Cloud, Dreamweaver, Illustrator, InDesign, Ink, Line, Muse, Photoshop, Premiere, Sketch and Slide are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.

Wednesday, June 18th, 2014 Uncategorized Comments Off on (ADBE) Announces All New 2014 Release of Creative Cloud

(SWSH) Regains NASDAQ Listing Compliance

CHARLOTTE, N.C., June 18, 2014  — Swisher Hygiene Inc. (“Swisher” or the “Company”) (Nasdaq:SWSH), a leading service provider of essential hygiene and sanitizing solutions, announced today that the company received a letter from NASDAQ on June 17, 2014 noting the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share. NASDAQ staff made the determination after Swisher’s bid price closed above $1.00 per share for the prior 10 consecutive business days.

Accordingly, NASDAQ will continue to list Swisher’s securities on The NASDAQ Capital Market and considers the matter closed.

About Swisher Hygiene Inc.

Swisher Hygiene Inc. is a NASDAQ listed service company delivering essential hygiene and sanitizing solutions to customers in a wide range of end-markets, with a particular emphasis on the foodservice, hospitality, retail and healthcare industries. These solutions are typically delivered by employees on a regularly scheduled basis and involve providing Swisher’s customers with consumable products such as detergents, cleaning chemicals, soap, paper, water filters and supplies, together with the rental and servicing of dish machines and other equipment for the dispensing of those products, as well as additional services such as the cleaning of restrooms and other facilities. Swisher is committed to service excellence, as what Swisher does matters to thousands of customers on a daily basis, helping to create the cleanest and healthiest environments.

CONTACT: For Further Information, Please Contact:

         Swisher Hygiene Inc.

         Investor Contact:
         Amy Simpson
         Phone: (704) 602-7116

         Garrett Edson, ICR
         Phone: (203) 682-8331
Wednesday, June 18th, 2014 Uncategorized Comments Off on (SWSH) Regains NASDAQ Listing Compliance

(MEAS) to Be Acquired By (TELL)

Transaction Establishes TE as a Leader in the High-Growth Sensor Market; Further Expands TE’s Leadership Position in Harsh Environment Applications Expected to be Accretive to 2015 Adjusted EPS

SCHAFFHAUSEN, Switzerland, June 18, 2014  — TE Connectivity Ltd. (NYSE: TEL), a world leader in connectivity, announced today that it has entered into a definitive agreement to acquire Measurement Specialties, Inc. (NASDAQ: MEAS) for $86 cash per share or a total transaction value of approximately $1.7 billion (including assumption of net debt).

Measurement Specialties, a leading global designer and manufacturer of sensors and sensor-based systems with expected revenue of $540 million in its current fiscal year, offers a broad portfolio of sensor technologies including pressure, vibration, force, temperature, humidity, ultrasonics, position and fluid, for a wide range of applications and industries.

“The acquisition of Measurement Specialties is a key part of our strategy to be a leader in the very attractive, high-growth sensor industry and adds nearly $40 billion to our addressable market,” said Tom Lynch, TE Connectivity Chairman and CEO. “We are excited about this acquisition as it enables TE to provide customers with an unmatched range of connectivity and sensor solutions that are essential in a world where everything is increasingly connected. We look forward to combining Measurement Specialties’ strong breadth of products and technologies with our deep customer relationships and global scale. We are also delighted to welcome their talented team to TE.”

Frank Guidone, CEO of Measurement Specialties, said, “The sensor market is quite strong, with both the number of applications and the content per unit increasing every year. We are excited to expand our product offerings to customers around the world through TE’s unparalleled go-to-market capabilities. We look forward to working with TE toward a seamless integration for our customers and employees, and becoming the supplier of choice for customers’ sensing requirements.”

Strategic Rationale
The strategic rationale for the acquisition of Measurement Specialties is as follows:

Establishes a leadership position in the attractive sensor market: The combination of TE’s sensor business with Measurement Specialties’ leading range of sensors and sensor systems establishes TE as one of the largest sensor companies in the world.  The sensor market is a fragmented, large and high-growth market, and the acquisition increases TE’s addressable market by nearly $40 billion. TE’s scale will be unique in this market.

Accelerates sales and profit growth: TE’s scale coupled with Measurement Specialties’ broad sensor product range is expected to create double-digit growth in TE’s sensor business.  TE’s deep OEM relationships, unparalleled go-to-market resources, engineering strength, leadership in harsh environment applications, and global footprint are the underlying factors driving this growth. TE also expects to achieve significant cost and tax synergies and generate attractive financial returns for its shareholders.

Increases TE content: The combination of Measurement Specialties with TE creates the leading provider of highly engineered connectivity and sensor solutions. This combination will enable TE to provide a broader range of solutions for its customers and will increase TE’s content per application.

Financial Highlights
The company expects mid-single digit accretion to TE’s adjusted EPS in the first year, excluding acquisition related costs.

The transaction will be financed through cash and additional debt. The transaction is subject to the receipt of certain regulatory approvals, approval of Measurement Specialties’ shareholders and other customary closing conditions. The transaction is expected to close in calendar year 2014.

TE’s financial advisors are Citi and Centerview Partners LLC and outside counsel is Davis Polk & Wardwell LLP.  Barclays is the exclusive financial advisor and provider of the fairness opinion to the Measurement Specialties’ Board of Directors. DLA Piper is outside counsel to Measurement Specialties.

Conference Call And Webcast For Investors
The company will hold a conference call for investors today beginning at 5:00 p.m. EDT and can be accessed as follows.  In the United States, dial 800-230-1093; International: 612-288-0340.

Internet users will be able to access the company’s webcast, including slide materials, at the “Investors” section of TE Connectivity’s website at http://investors.te.com/.

An audio replay of the conference call will be available beginning at 7:00 p.m. EDT on June 18, 2014, and ending on June 25, 2014.  The dial-in number for participants in the U.S. is 800-475-6701.  For participants outside the U.S., the replay dial-in is 320-365-3844, access code: 329902.

Non-GAAP Measure
The earnings per share (“EPS”) amount described in the eighth paragraph of this release is a non-GAAP (U.S. generally accepted accounting principles) measure and should not be considered a replacement for GAAP results. We use diluted EPS from continuing operations attributable to TE Connectivity Ltd. before special items, including charges or income related to legal settlements and reserves, restructuring and other charges, acquisition related charges, impairment charges, tax sharing income related to certain proposed adjustments to prior period tax returns and other tax items, certain significant special tax items, other income or charges, if any, and, if applicable, related tax effects (“Adjusted EPS”). We use Adjusted EPS because we believe that it is appropriate for investors to consider results excluding these items in addition to results in accordance with GAAP. We believe such a measure provides a picture of our results that is more comparable among periods since it excludes the impact of special items, which may recur, but tend to be irregular as to timing, thereby making comparisons between periods more difficult. It also is a significant component in our incentive compensation plans. The limitation of this measure is that it excludes the financial impact of items that would otherwise either increase or decrease our reported results. This limitation is best addressed by using Adjusted EPS in combination with diluted EPS from continuing operations attributable to TE Connectivity Ltd. (the most comparable GAAP measure) in order to better understand the amounts, character and impact of any increase or decrease on reported results.  With regard to the forward-looking financial measure of our forecasted Adjusted EPS, reconciliation to the applicable forward-looking forecasted GAAP financial measure is not provided because it is not available without unreasonable effort.

Cautionary Statement Regarding Forward-Looking Statements
This release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual results, performance, financial condition or achievements to differ materially from anticipated results, performance, financial condition or achievements. All statements contained herein that are not clearly historical in nature are forward-looking and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. We have no intention and are under no obligation to update or alter (and expressly disclaim any such intention or obligation to do so) our forward-looking statements whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements in this release include statements addressing our future financial condition and operating results; our ability to fund and consummate the transaction, including the entry into financing arrangements and the receipt of regulatory approvals; and our ability to realize projected financial impacts of and to integrate the acquisition. Examples of factors that could cause actual results to differ materially from those described in the forward-looking statements include, among others, business, economic, competitive and regulatory risks, such as conditions affecting demand for products, particularly in the automotive industry and the telecommunications networks and consumer devices industries; competition and pricing pressure; fluctuations in foreign currency exchange rates and commodity prices; natural disasters and political, economic and military instability in countries in which we operate; developments in the credit markets; future goodwill impairment; compliance with current and future environmental and other laws and regulations; the possible effects on us of changes in tax laws, tax treaties and other legislation; the risk that the transaction may not be consummated; the risk that a regulatory approval that may be required for the transaction is not obtained or is obtained subject to conditions that are not anticipated; the risk that Measurement Specialties’ operations will not be successfully integrated into ours; and the risk that revenue opportunities, cost savings and other anticipated synergies from the transaction may not be fully realized or may take longer to realize than expected. More detailed information about these and other factors is set forth in TE Connectivity Ltd.’s Annual Report on Form 10-K for the fiscal year ended Sept. 27, 2013 as well as in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed by us with the U.S. Securities and Exchange Commission (“SEC”).

Additional Information And Where To Find It

This communication is for informational purposes only and does not constitute an offer to purchase or a solicitation of any proxy, vote or approval. In connection with the proposed merger, Measurement Specialties, Inc. (“MEAS”) intends to file a proxy statement and related documents with the SEC.  The definitive proxy statement will be mailed to MEAS shareholders.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of the proxy statement and other relevant documents (in each case when available) filed by MEAS and TE Connectivity Ltd. with the SEC at the website maintained by the SEC at www.sec.gov. Copies of the documents filed by MEAS with the SEC will be available free of charge at the website maintained by MEAS at www.meas-spec.com. Copies of the documents filed by TE Connectivity Ltd. with the SEC will be available free of charge at the website maintained by TE at www.te.com.

MEAS and its directors, executive officers and certain other employees may be deemed to be participants in the solicitation of proxies from MEAS’ shareholders with respect to the proposed merger.  Information about MEAS’ directors and executive officers and their ownership of MEAS’ common stock is set forth in the proxy statement for MEAS’ 2013 Annual Meeting of Stockholders, which was filed with the SEC on July 29, 2013, and MEAS’ Annual Report on Form 10-K for the fiscal year ended March 31, 2014, which was filed with the SEC on June 3, 2014.  Additional information regarding persons who may be deemed to be participants in the solicitation of proxies in respect of the proposed merger will be contained in the proxy statement to be filed by MEAS with the SEC.

ABOUT TE CONNECTIVITY
TE Connectivity (NYSE: TEL) is a $13 billion world leader in connectivity. The company designs and manufactures products at the heart of electronic connections for the world’s leading industries including automotive, energy and industrial, broadband communications, consumer devices, healthcare, and aerospace and defense. TE Connectivity’s long-standing commitment to innovation and engineering excellence helps its customers solve the need for more energy efficiency, always-on communications and ever-increasing productivity. With nearly 90,000 employees in over 50 countries, TE Connectivity makes connections the world relies on to work flawlessly every day. To connect with the company, visit: www.TE.com.

ABOUT MEASUREMENT SPECIALTIES
Measurement Specialties, Inc. (NASDAQ: MEAS) designs and manufactures sensors and sensor-based systems to measure precise ranges of physical characteristics such as pressure, temperature, position, force, vibration, humidity and photo optics. Measurement Specialties uses multiple advanced technologies – piezo-resistive silicon sensors, application-specific integrated circuits, micro-electromechanical systems (“MEMS”), piezoelectric polymers, foil strain gauges, force balance systems, fluid capacitive devices, linear and rotational variable differential transformers, electromagnetic displacement sensors, hygroscopic capacitive sensors, ultrasonic sensors, optical sensors, negative thermal coefficient (“NTC”) ceramic sensors, mechanical resonators and submersible hydrostatic level sensors – to engineer sensors that operate precisely and cost effectively.

Wednesday, June 18th, 2014 Uncategorized Comments Off on (MEAS) to Be Acquired By (TELL)

(LIVE) Announces Increased Success in New Customer Acquisition

LiveDeal Inc. (NASDAQ:LIVE) (“LiveDeal” or the “Company”), a publicly traded company that operates livedeal.com, a geo-location based mobile marketing platform that enables restaurants to publish “real-time” and “instant offers” to nearby consumers, today announces that it has continued to see significant uptake of restaurants offering consumers deals on their platform as well as new restaurants registering for its services.

Over the last several months, LiveDeal has actively sought to increase restaurant uptake, including its recent 35-city ad campaign and other activities. As a result, the company has experienced a more than 400-percent increase in the number of restaurants that register with LiveDeal’s unique, real-time “deal engine” on a daily basis.

“We are encouraged by the feedback we’ve received from restaurants across the many markets where our partners are providing their customers with deal opportunities, as well as the significant increase in the number of partners that sign up with us each day ” said Jon Isaac, CEO of LiveDeal, Inc. “We regularly receive reports that LiveDeal’s unique engine is helping to stimulate its customers restaurants’ business, and providing tremendous value for their investment, which we believe contributes to the regular daily increase in new clients. ”

About LiveDeal, Inc.
LiveDeal Inc. provides marketing solutions that boost customer awareness and merchant visibility on the Internet. LiveDeal operates a deal engine, which is a service that connects merchants and consumers via an innovative platform that uses geo-location, enabling businesses to communicate real-time and instant offers to nearby consumers. In November 2012, LiveDeal commenced the sale of marketing tools that help local businesses manage their online presence under the Company’s Velocity Local™ brand. LiveDeal continues to actively develop, revise, and evaluate these products and services and its marketing strategies and procedures. For more information, visit www.livedeal.com.

Forward-Looking and Cautionary Statements
This press release contains “forward-looking” statements that are based on present circumstances and on LiveDeal’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements, including any statements regarding the plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance, are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. Forward-looking statements are made only as of the date of this release and LiveDeal does not undertake and specifically declines any obligation to update any forward-looking statements. Readers should not place undue reliance on these forward-looking statements.

Wednesday, June 18th, 2014 Uncategorized Comments Off on (LIVE) Announces Increased Success in New Customer Acquisition

(RARE) to Present at the JMP Securities Healthcare Conference

Novato, CA, June 18, 2014  — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer, will be presenting at the JMP Securities Healthcare Conference on June 25, 2014 at 2:30pm ET at the Westin New York Grand Central.

The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available approximately one hour after the conclusion of the live presentation and will be available for 180 days.

About Ultragenyx

Ultragenyx is a development-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

CONTACT: Contact Ultragenyx Pharmaceutical Inc.
         844-758-7273
         For Media, Bee Nguyen
         For Investors, Robert Anstey
Wednesday, June 18th, 2014 Uncategorized Comments Off on (RARE) to Present at the JMP Securities Healthcare Conference

(MEIL) to Supply More Than $6M of Biodiesel to U.S.

LAS VEGAS, NV–(Jun 18, 2014) – Methes Energies International Ltd. (NASDAQ: MEIL), a renewable energy company that offers an array of products and services to biodiesel fuel producers, today announced that, pursuant to previously announced preliminary arrangements, it has entered into agreements with U.S. clients to supply more than $6 million of biodiesel (including Methes Energies’ share of the expected biodiesel blender’s tax credit) by September 30, 2014. The agreements require shipment of approximately 1.4 million gallons of biodiesel over this period, commencing around June 23rd. Though these agreements are part of an expected longer term relationship, Methes Energies did not want to commit to shipments over a longer period in a sometimes volatile market.

The agreements also cover the potential reinstatement of the Biodiesel Blender’s Tax Credit (“BTC”) of $1.00 per gallon in the United States. In the event that the BTC is reinstated retroactively, a majority of the BTC claimed by Methes Energies’ clients will be transferred to Methes Energies.

Nicholas Ng, President of Methes Energies, said, “Production is currently going very well and we’ll be ramping up very quickly over the next few weeks. We’ve locked in our feedstock price as well as our selling price for the next 3 months. We see some upside moving forward so we are comfortable with a 3-month at the time strategy with the volume committed in these agreements. We are also in a great position to move more biodiesel on the spot market where we believe we can make more money.”

About Methes Energies International Ltd.

Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada, and at its 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

Forward-looking Statements

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended November 30, 2013, filed on February 25, 2014, as amended, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:
Methes Energies International Ltd.
Michel G. Laporte
Chairman and CEO
702-932-9964

Wednesday, June 18th, 2014 Uncategorized Comments Off on (MEIL) to Supply More Than $6M of Biodiesel to U.S.

(WATT) to Participate in Oppenheimer 2nd Annual Emerging Innovations Conference

PLEASANTON, CA–(Jun 17, 2014) – Energous Corporation (“Energous” or “the Company”) (NASDAQ: WATT), the developer of WattUp™, a disruptive wire-free charging technology, announced that it will attend the Oppenheimer 2nd Annual Emerging Innovations Conference at the Grand Hyatt Hotel in New York City on June 18, 2014.

Stephen R. Rizzone, Chairman, President, and Chief Executive Officer will be available for one-on-one meetings with investors in attendance.

Date: Wednesday, June 18, 2014
Location: Grand Hyatt Hotel, New York City

Registration for the conference and for one-on-one meetings is mandatory. Please contact your Oppenheimer contact for additional information.

About Energous Corporation

Energous Corporation is developing WattUp™, a wire-free charging technology that will transform the way people charge and power their electronic devices at home, in the office, in the car and beyond. WattUp is a revolutionary, patent- and trademark-pending solution that delivers intelligent, scalable power via the same radio bands as a Wi-Fi router. WattUp differs from current wireless charging systems in that it delivers meaningful, useable power, at a distance, while allowing users to roam while charging. The result is a wire-free experience that saves users from having to remember to plug in their devices or place them on a mat. Energous will initially license WattUp to the wearable and mobile-accessory markets and will expand to other markets such as Wi-Fi routers and smartphones over time. For more information, please visit www.energous.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements”. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed registration statement on Form S-1. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward -looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

MZ North America
Matt Hayden
Chairman
Direct: +1-949-259-4986
Email: matt.hayden@mzgroup.us
Web: www.mzgroup.us

Tuesday, June 17th, 2014 Uncategorized Comments Off on (WATT) to Participate in Oppenheimer 2nd Annual Emerging Innovations Conference

(IDSA) Announces New Appointments to its Board of Directors

Industrial Services of America, Inc. (NASDAQ: IDSA), a company that buys, processes and markets ferrous and non-ferrous metals and other recyclable commodities, and offers waste management programs and equipment to commercial customers, today announced the appointment of three new members to its Board of Directors: William B. Yarmuth, Vincent J. Tyra and Sean Garber.

Mr. Yarmuth is Chairman and CEO of Almost Family, Inc., a Louisville, Kentucky-based provider of home health services. Almost Family provides a range of Medicare-certified home health nursing services to patients in need of recuperative and other care. It also provides personal care, medication management, meal preparation, caregiver respite, and homemaking services for patients. Mr. Yarmuth has been a director of Almost Family since 1991, when Almost Family acquired National Health Industries, where Mr. Yarmuth was Chairman, President and Chief Executive Officer. Mr. Yarmuth has been instrumental in growing Almost Family to the $400 million revenue company that it is today.

Vincent J. Tyra is President of ISCO Industries, a global, customized piping solutions provider based in Louisville, Kentucky. Prior to his position at ISCO, Mr. Tyra was a Managing Partner at Southfield Capital, a private investment firm based in Greenwich, Connecticut. Mr. Tyra continues to be an Operating Partner with Southfield Capital, serves on the firm’s investment committee and is a board member of various Southfield Capital portfolio companies. Prior to Southfield Capital, Mr. Tyra was CEO of Broder Bros. Co., a wholesale distributor of imprintable activewear, where he grew the company’s revenue from $315 million to $1 billon over a six-year period. Prior to joining Broder, Mr. Tyra served as President of Retail and Activewear at Fruit of the Loom, where he helped orchestrate the successful reorganization and turnaround of a $2 billion retail consumer packaged goods company. Previous to Fruit of the Loom, Mr. Tyra was a principal investor and Executive Vice President of TSM, a Louisville, Kentucky based wholesale distributor of activewear.

Sean Garber is President of Algar, Inc., a company specializing in the sale of new and used auto parts, as well as in automobile and metal recycling. Pursuant to the previously announced Management Services Agreement between Algar and Industrial Services of America, Algar provides the Company with day-to-day senior executive level operating management supervisory services and Mr. Garber serves as President of Industrial Services of America. Prior to joining Algar in 2005, Mr. Garber owned Riverside Mortgage, Inc., a residential mortgage brokerage company, which he sold in 2006. Before Riverside Mortgage, Inc., Mr. Garber owned and operated CMJ Ventures, LLC, a trademarked and licensed apparel business.

The Company also announced the resignation from its Board of Directors of Alan Gildenberg, a member of the Board since 2012.

Pursuant to the Management Services Agreement, Algar had the right to nominate two new directors any time following the effective date of the Management Services Agreement. Algar nominated Mr. Yarmuth and Mr. Tyra for appointment to the Board of Directors. The Board nominated Mr. Garber. In connection with these nominations, the Board of Directors increased the number of directors which constitute the entire Board of Directors from five to seven and affirmatively determined that Messrs. Yarmuth and Tyra satisfy the criteria to be independent directors as set forth in Nasdaq Listing Rule 5605.

Orson Oliver, Chairman of the Board of ISA, stated, “We are pleased to welcome the three new directors to ISA. This group brings a complement of skills and experience to the Company, not to mention a wealth of fresh ideas. We believe we have assembled a team with the right combination of industry knowledge and experience to guide ISA’s strategy and future growth. We also thank Alan Gildenberg for his faithful service to the Company and its shareholders.”

About ISA

Headquartered in Louisville, Kentucky, Industrial Services of America, Inc., is a publicly traded company whose core business is buying, processing and marketing scrap metals and recyclable materials for domestic users and export markets. Additionally, ISA offers commercial, industrial and business customers a variety of programs and equipment to manage waste. More information about ISA is available at www.isa-inc.com. ISA’s SEC filings are available for review at the Securities and Exchange Commission web site at http://www.sec.gov/edgar/searchedgar/companysearch.html.

This news release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Specific risks include fluctuations in the price of recycled materials; varying demand for waste managing systems, equipment and services; competitive pressures in waste managing systems and equipment; our ability to successfully integrate the operations of acquired businesses, if any, and achieve expected synergies and operating efficiencies from the acquisition, in each case within expected time-frames or at all; competitive pressures in the waste managing business; and loss of customers. Further information on factors that could affect ISA’s results is detailed in ISA’s filings with the Securities and Exchange Commission. ISA undertakes no obligation to publicly release the results of any revisions to the forward-looking statements.

Tuesday, June 17th, 2014 Uncategorized Comments Off on (IDSA) Announces New Appointments to its Board of Directors

(RGSE) Sunetric Designs and Deploys Solar-to-Grid Curtailment Solution

Solar Solution Provides Energy Curtailment to Overcome Utility Grid Saturation Concerns

LOUISVILLE, Colo. and KAILUA, Hawaii, June 17, 2014  — Sunetric, a wholly-owned subsidiary of RGS Energy (Nasdaq:RGSE), has deployed a 198.8 kilowatt (kW) photovoltaic (PV) system with automated curtailment and smart-grid controls at a popular beachfront resort on the island of Kauai in Hawaii. The system is funded and owned by Kairos Energy Capital, a Hawaii-based merchant bank which finances and invests in solar.

The system assures all electricity generated by the PV system is consumed by the local facility and not fed back into the utility grid. This reduces the impact on the local circuit and makes it easier for the island’s electric utility provider, Kauai Island Utility Cooperative (KIUC), to manage the grid.

The solution addresses the concerns of KIUC and other utilities regarding “grid saturation,” where electricity generated by a solar PV system exceeds the maximum amount allowed on a particular circuit. Since Sunetric’s PV system intelligently avoids flowing electricity back onto the grid, it resolves this issue while providing customers the economic and environmental benefits of solar energy.

This Kauai project incorporates solar panels onto a parking canopy and is expected to save the resort more than $30,000 annually in energy costs. KIUC has been closely monitoring the PV system through interval data and confirms the solar array has not exported power to the grid. The Sunetric engineering team spent four months developing, testing and implementing this custom solution, which now serves as an excellent model for PV installations where interconnection capacity is a concern.

“We partnered with Sunetric to deploy this unique solution because they are one of the largest and most well established local solar developers and installers in Hawaii,” said Larry Gilbert, managing partner and CEO at Kairos Energy Capital. “The Sunetric team brought great engineering know-how and top-notch service to the project, which has become one of our most innovative solar technologies to date. Sunetric now supports our ongoing efforts to help businesses ‘go green’ by adopting solar.”

Sunetric’s president, Aaron Kirk, commented: “We are committed to meeting our customers’ special requirements, and we thrive on tackling challenges like this one that involve designing and installing an unconventional curtailment system. It represents our first solar-to-grid curtailment solution that overcomes utility grid saturation concerns common in the Hawaiian Islands. This popular Kauai resort has now created a more sustainable future for themselves and their guests, and we expect other Hawaii resort properties to follow.”

About Kairos Energy Capital
Kairos Energy Capital is a Hawaii-based merchant bank which finances and invests in solar, wind and other renewable energy projects in Hawaii. Kairos and its principals were the first Hawaii-based company to successfully implement commercial power purchase agreement financing for solar PV in Hawaii, and continue to be one of the leading providers of PPA financing for commercial, non-profit and condominium solar projects. For more information, visit www.kairosenergycapital.com.

About Sunetric
Sunetric is one of the largest and most experienced solar developers and integrators in Hawaii. As a full-service solar energy firm, the company handles every stage of the design, development and installation of photovoltaic systems on Oahu, Maui, Kauai, Molokai, Lanai and the Big Island. Sunetric is a wholly owned subsidiary of RGS Energy. For more information, visit http://sunetric.com/.

About RGS Energy
RGS Energy (Nasdaq:RGSE) is one of the nation’s pioneering solar energy companies serving commercial, residential, and utility customers. Beginning with one of the very first photovoltaic panels sold to the public in the U.S. in 1978, the company has installed more than 22,500 solar power systems representing over 235 megawatts of 100% clean renewable energy. RGS Energy makes it very convenient for customers to save on their energy bills by providing a comprehensive solar solution, from design, financing, permitting and installation to ongoing monitoring, maintenance and support.

As one of the nation’s largest and most experienced solar power players, the company has 20 offices across the U.S. For more information, visit RGSEnergy.com, on Facebook at www.facebook.com/rgsenergy and on Twitter at https://twitter.com/rgsenergy. RGS Energy is a trade name and RGS Energy makes filings with the Securities and Exchange Commission under its official name “Real Goods Solar, Inc.”

Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements relating to matters that are not historical facts. Forward-looking statements may be identified by the use of words such as “expect,” “intend,” “believe,” “will,” “should” or comparable terminology or by discussions of strategy. While RGS Energy believes its assumptions and expectations underlying forward-looking statements are reasonable, there can be no assurance that actual results will not be materially different. Risks and uncertainties that could cause materially different results include, among others, RGS Energy’s failure to successfully complete future projects, introduction of new products and services, completion and integration of acquisitions, possibility of negative impact from weather conditions, supplier delivery disruptions, possibility of negative economic conditions and other risks and uncertainties included in RGS Energy’s filings with the Securities and Exchange Commission. RGS Energy assumes no duty to update any forward-looking statements.

CONTACT: Media and Investor Relations Contact for RGS Energy:
         Ron Both
         Liolios Group, Inc.
         Tel 1-949-574-3860
         RGSE@liolios.com

         Sunetric Media Contact
         Hannah Lee
         Marketing Manager
         Tel 1-808-262-6600
         hlee@sunetric.com
Tuesday, June 17th, 2014 Uncategorized Comments Off on (RGSE) Sunetric Designs and Deploys Solar-to-Grid Curtailment Solution

(SCTY) to Acquire Silevo

Details Available on SolarCity’s Blog; Elon Musk, Peter Rive and Lyndon Rive to Discuss Live at 10 AM ET / 7 AM PT

SAN MATEO, Calif., June 17, 2014  — SolarCity Corporation (Nasdaq:SCTY), has signed a definitive agreement to acquire Silevo, a solar technology and manufacturing company whose modules have achieved a unique combination of high energy output and low cost. The transaction was announced, and its significance described in detail, in a post from SolarCity Chairman Elon Musk, Co-founder and Chief Technology Officer Peter Rive and Co-founder and Chief Executive Officer Lyndon Rive on SolarCity’s blog, available at: http://blog.solarcity.com/silevo/. Mr. Musk and Messrs. Rive will host a conference call to discuss the proposed acquisition today, Tuesday, June 17, 2014, at 10:00 a.m. Eastern Time. For additional details regarding the proposed acquisition, please review our current report on Form 8-K filed today with the Securities and Exchange Commission.

The conference call can be accessed live over the phone by dialing 1-877-407-0784, or for international callers, 1-201-689-8560. A replay will be available two hours after the call and can be accessed by dialing 1-877-870-5176, or for international callers, 1-858-384-5517. The passcode for the live call and the replay is 13585224. The replay will be available until June 24, 2014.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging on at the “Events and Presentations” link of the Investor Relations section of the Company’s website at http://investors.solarcity.com/events.cfm. The on-line replay will be available for a limited time beginning immediately following the call.

About SolarCity

SolarCity® (Nasdaq:SCTY) provides clean energy. The company has disrupted the century-old energy industry by providing renewable electricity directly to homeowners, businesses and government organizations for less than they spend on utility bills. SolarCity gives customers control of their energy costs to protect them from rising rates. The company makes solar energy easy by taking care of everything from design and permitting to monitoring and maintenance. SolarCity currently serves 15 states and signs a new customer every two minutes. Visit the company online at www.solarcity.com and follow the company on Facebook & Twitter.

CONTACT: Investor Contact
         Aaron Chew
         650-963-5920
         investors@solarcity.com

         Media Contact
         Molly Canales
         650-963-5674
         press@solarcity.com
Tuesday, June 17th, 2014 Uncategorized Comments Off on (SCTY) to Acquire Silevo

(BIOL) Announces Significant Leadership Changes

Paul Clark Named Chairman of the Board of Directors Jeffrey Nugent Appointed Interim CEO While Search for Permanent CEO Begins

IRVINE, CA–(Jun 17, 2014) – BIOLASE, Inc. (NASDAQ: BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced a series of moves with the intention of strengthening the Company’s leadership, worldwide competitiveness and the focus on its professional customers and their patients.

With the decisive confirmation from the Delaware Supreme Court on June 12, 2014, of the Delaware Chancery Court’s May 21, 2014 ruling, the Board of Directors (the “Board”) has been established as Mr. Paul Clark, Dr. Fred Moll, Dr. Norman Nemoy, Mr. Federico Pignatelli, and Mr. Jim Talevich. The Board today added Mr. Jeffrey Nugent as the sixth member of the Board.

Following the Delaware Supreme Court’s ruling, on June 12, 2014 Mr. Pignatelli resigned from his roles as Chairman and Chief Executive Officer (“CEO”).

Also today, the Board elected Mr. Clark as Chairman of the Board. Mr. Clark served as Chairman, CEO, and President of ICOS Corporation, which was acquired by Lilly in 2007 for $2.2 billion. Previously, he was the President of Abbott’s Pharmaceuticals Division. While at Abbott, sales grew from $250 million to $2.6 billion during his tenure as President. Mr. Clark received a B.A. in finance from the University of Alabama and an MBA from Dartmouth College. Mr. Clark said, “BIOLASE’s technology leadership, dominant market position, dedicated employees, valuable patent portfolio, and product pipeline make it an exciting opportunity.”

Mr. Nugent has accepted the role of interim CEO while a formal search is initiated to appoint a permanent CEO. Mr. Nugent has a broad background in medical devices, including aesthetic lasers technology and the responsibility for leading the Johnson & Johnson Dental care franchise, as well as a number of aesthetic dermatology companies. Most recently, Mr. Nugent was Worldwide President and CEO of Neutrogena, one of the most successful acquisitions in Johnson & Johnson’s history, President and CEO of Revlon, and Founder, President and CEO of Precision Dermatology, recently acquired by Valeant. Mr. Nugent has a B.S. in mathematics and an MBA in finance and marketing from Loyola University of Chicago. Mr. Nugent said, “BIOLASE has significant upside potential on a global scale, and I look forward to contributing to its success.”

The Company looks forward to establishing a positive relationship with its distributors, partners, investors, and the dental and medical professional communities upon whose trust and confidence it depends.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers; products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 25,000 laser systems. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.
212-564-4700

Tuesday, June 17th, 2014 Uncategorized Comments Off on (BIOL) Announces Significant Leadership Changes

(GIGA) $2.4 Million Order From the U.S. Navy $2.4 Million Order From the U.S. Navy

SAN RAMON, Calif., June 17, 2014  — Giga-tronics Incorporated announced today that it has received an order from the Naval Air Warfare Center in Pawtuxet River, MD valued at approximately $2.4 million associated with its Model 8003 Precision Scalar Analyzer. The Company anticipates shipping the equipment to the Navy over the next six months.

The Giga-tronics Model 8003 Precision Scalar Analyzer combines fast measurement capability with the accuracy and linearity of a power meter in a single instrument. John Regazzi, President and CEO of Giga-tronics, said “We are committed to supporting the U.S. Navy’s requirement for high accuracy device calibration and are pleased to be selected as a supplier of critical equipment for their metrology labs.”

Giga-tronics is a publicly held company, traded on the NASDAQ Capital Market under the symbol “GIGA”. Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.

This press release contains forward-looking statements concerning profitability, development of products, future growth, shareholder value, backlog and shipments. Actual results may differ significantly due to risks and uncertainties, such as future orders, cancellations or deferrals, disputes over performance, availability of capital and capital resources, the ability to collect receivables and general market conditions. For further discussion, see Giga-tronics’ most recent annual report on Form 10-K for the fiscal year ended March 30, 2013, Part I, under the heading “Risk Factors” and Part II, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

CONTACT: Steven D. Lance
         Vice President of Finance/Chief Financial Officer
         slance@gigatronics.com
         (925) 302-1056
Tuesday, June 17th, 2014 Uncategorized Comments Off on (GIGA) $2.4 Million Order From the U.S. Navy $2.4 Million Order From the U.S. Navy
Top Small Cap Market News